AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021  Page 1 of 106  
 CLINICAL STUDY PROTOCOL  
Phase 2, Multicenter, Randomized, Double -Blind, Placebo -Controlled Study 
to Assess the Safety and Efficacy of Viralym -M (ALVR105)  Compared to 
Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV- 6, and JCV 
Infection and/or Disease, in High -Risk Patients After Allogeneic 
Hematopoietic Cell Transplant  
Investigational Product: ALVR105 ( Viralym -M) 
Protocol Number: P-105-202 
IND:  [ADDRESS_889614]:  N/A 
Sponsor:  
AlloVir Kirby [CONTACT_594888]  
[ADDRESS_889615]  
Houston, TX [ZIP_CODE] [LOCATION_002]  
Telephone: 936 -662-3626 
Fax: 979-289 -7437 
FINA
L PROTOCOL 
Version
 Number : 3.0 
Original Protocol: 13 July 2020 
Amendment 1:  27 October 2020 
Amendment 2:  07 Apr  2021 
Confidentiality Statement  
The information in this document is confidential and is not to be disclosed without the 
written consent of AlloVir except to the extent that disclosure would be required by [CONTACT_344151]/or conducting a clinical study for AlloVir. You are 
allowed to disclose the contents of this document only to your Institutional Review Board 
or Independent Ethics Committee and study personnel directly involved with conducting 
this protocol. Persons to whom the information is disclosed must be informed that the 
information is confidential and proprietary to AlloVir and that it may not be further 
disclosed to third parties. 
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 7 of 106  
 INVESTIGATOR AGREEMENT  
By [CONTACT_31300], I agree that: 
I have read this protocol, Phase 2, Multicenter, Randomized, Double-Blind, Placebo-
Controlled Study to Assess the Safety and Efficacy of ALVR105  (Viralym- M) Compared to 
Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High -Risk Patients After Allogeneic Hematopoietic Cell Transplant. I approve this 
document and I agree that it contains all necessary details for carrying out the study as described. I will conduct this study in accordance with the design and specific provision of this protocol and will make a reasonable effort to complete the study within the time designated. I will provide copi[INVESTIGATOR_659645] r my supervision. I will discuss this material with them to 
ensure they are fully informed about the study product and study procedures. I will let them know that this information is confidential and proprietary to AlloVir and that it may not be further di sclosed to third parties. I understand that the study may be terminated or enrollment 
suspended at any time by [CONTACT_594892], with or without cause, or by [CONTACT_120304]. 
I agree to conduct this study in full accordance with Food and Drug Administration 
Regulations, Institutional Review Board/Ethic Committee Regulations, and International Council for Harmonisation Guidelines for Good Clinical Practices and applicable national or regional regulations and guidelines. 
 
  
 
     
 
 
 
Investigator’s Signature [CONTACT_659688]’s Printed Name  
 
  
[CONTACT_659689] P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 8 of 106  
  
TABLE OF CONTENTS  
 
Signature [CONTACT_3490]  ............................................................................................................................... 2  
INVESTIGATOR AGREEMENT .................................................................................................. 7  
1. Protocol Summary  ................................................................................................................. 16  
1.1. Synopsis ..................................................................................................................... 16  
1.2. Schema  ....................................................................................................................... 21  
1.3. Schedules of Acti vities  .............................................................................................. 22  
2. INTRODUCTION  ................................................................................................................. 35  
2.1. Study Rationale .......................................................................................................... 35  
2.2. Backgro und ................................................................................................................ 35  
2.2.1.  Overview of Nonclinical Studies with  ALVR105  ...................................... 36  
2.2.2.  Overview of Clinical Studies with Virus -Specific T  Cells  ......................... 36  
2.3. Benefit/Risk Assessment  ........................................................................................... 37  
2.3.1.  Potential Benefits  ........................................................................................ 37  
2.3.2.  Potential Risks  ............................................................................................. 37  
3. OBJECTIVES AND ENDPOINTS  ....................................................................................... 39  
4. STUDY DESIGN  .................................................................................................................. 42  
4.1. Overall Design  ........................................................................................................... 42  
4.2. Scientific Rationale for Study Design  ....................................................................... 44  
4.3. Justification for Dose ................................................................................................. 44  
4.4. End of Study Definition ............................................................................................. 45  
4.4.1.  Meals and Dietary  Restrictions  ................................................................... 45  
5. STUDY POPULATION  ........................................................................................................ 46  
5.1. Inclusion Criteria  ....................................................................................................... 46  
5.2. Exclusion Criteria  ...................................................................................................... 48  
5.3. Lifestyle Restrictions  ................................................................................................. 49  
5.3.1.  Caffeine, Alcohol, and Tobacco  .................................................................. 49  
5.3.2.  Activity  ........................................................................................................ 49  
5.4. Screen Failur es ........................................................................................................... 49  
6. STUDY INTERVENTION(S) AND CONCOMITANT  THERAPY  ................................... 50  
6.1. Study Intervention(s) Administered .......................................................................... 50  
6.1.1.  Cell Line  Selection  ...................................................................................... 50  
6.1.2.  Study Intervention Administration  .............................................................. 51  
6.2. Preparation/Handling/Storage/Accountability ........................................................... 51  
6.2.1.  Study Drug Preparation and Dispensing ..................................................... 52  
6.2.2.  Storage and Accountability ......................................................................... 52  
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 9 of 106  
 6.3. Measures to Minimize Bias: Randomization and Blinding  ....................................... 52  
6.4. Study Intervention Compliance ................................................................................. 53  
6.5. Dose Modification ..................................................................................................... 53  
6.5.1.  Retreatment  Criteria  .................................................................................... 54  
6.6. Continued Access to Study Intervention after the End of the Study ......................... 54  
6.7. Treatment of Overdose  .............................................................................................. 54  
6.8. Concomitant Therapy ................................................................................................ 54  
6.8.1.  Excluded Medications and/or Procedures  ................................................... 54  
6.8.2.  Restricted Medications and/or Procedures .................................................. 55  
6.8.3.  Documentation of Prior and Concomitant Medication Use ........................ 55  
6.8.4.  Rescue Medication  ...................................................................................... 55  
7. DISCONTINUATION OF STUDY INTERVENTION AND  PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ............................................................................. 56  
7.1. Discontinuation of Study Intervention....................................................................... 56  
7.1.1.  Temporary  Discontinuation ......................................................................... 56  
7.1.2.  Rechallenge  ................................................................................................. 56  
7.2. Participant Discontinuation/Withdrawal from the Study  .......................................... [ADDRESS_889616] to Follow up ....................................................................................................... 57  
8. STUDY ASSESSMENTS AND PROCEDURES  ................................................................. 58  
8.1. Study Periods ............................................................................................................. 58  
8.1.1.  Pre-screening visit (optional) ...................................................................... 58  
8.1.2.  Screening  period .......................................................................................... 58  
8.1.3.  Treatment  period ......................................................................................... 59  
8.1.4.  Follow-up period ......................................................................................... 59  
8.2. Efficacy Assessments  ................................................................................................ 59  
8.2.1.  Definitions and Determination of  Viremia  .................................................. 59  
8.2.2.  Viral  Load  ................................................................................................... 59  
8.2.3.  Resolution of Viral Infections ..................................................................... 59  
8.2.4.  Quality of Life ............................................................................................. 60  
8.2.5.  Virus -specific T Cell  Assessment  ............................................................... 60  
8.3. Infection Assessments  ............................................................................................... 60  
8.3.1.  Confirmatory Plasma Samples for Suspected Infection .............................. 61  
8.3.2.  Samples When Initiating Anti- viral Therapy  .............................................. 61  
8.4. Safety Assessments  .................................................................................................... 61  
8.4.1.  Physical  Examinations ................................................................................ 61  
8.4.2.  Vital Signs ................................................................................................... 61  
8.4.3.  Electrocardiograms  ...................................................................................... 62  
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 10 of 106  
 8.4.4.  Clinical Safety Laboratory  Assessments ..................................................... 62  
8.4.5.  Pregnancy  Testing  ....................................................................................... 63  
8.4.6.  Suicidal Ideation and Behavior Risk Monitoring ........................................ 63  
8.5. Adverse Events (AEs), Serious Adverse Events (SAEs), and Other Safety Reporting
 ................................................................................................................................... [ADDRESS_889617]  .............................................................. 65  
8.6. Pharmacokinetics  ....................................................................................................... 66  
8.7. Genetics and/or Pharmacogenomics .......................................................................... 66  
8.8. Biomarkers  ................................................................................................................. 67  
8.9. Immunogenicity Assessments ................................................................................... 67  
8.10.  Medical Resource Utilization and Health Economics  ............................................... 67  
9. STATISTICAL CONSIDERATIONS  .................................................................................. 68  
9.1. Statistical Hypotheses ................................................................................................ 68  
9.2. Sample Size Determination  ....................................................................................... 68  
9.3. Analysis Populations ................................................................................................. 69  
9.4. Statistical Analyses  .................................................................................................... 69  
9.4.1.  General  Considerations ............................................................................... 69  
9.4.2.  Primary Efficacy  Endpoint .......................................................................... 69  
9.4.3.  Secondary Efficacy  Endpoints .................................................................... 70  
9.4.4.  Exploratory Endpoints ................................................................................. 71  
9.4.5.  Safety  Analysis ............................................................................................ 72  
9.4.6.  Other  Analyses  ............................................................................................ 72  
9.5. Interim Analyses  ........................................................................................................ 72  
9.5.1.  Stoppi[INVESTIGATOR_2121]  ......................................................................................... 72  
10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS ......... 74  
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ................... 74  
10.1.1.  Regulatory and Ethical Considerations ....................................................... 74  
10.1.2.  Financial  Disclosure .................................................................................... 74  
10.1.3.  Informed Consent Process  ........................................................................... 75  
10.1.4.  Data Protection  ............................................................................................ 75  
10.1.5.  Committee  Structure .................................................................................... 75  
10.1.6.  Dissemination of Clinical Study  Data ......................................................... 76  
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 11 of 106  
 10.1.7.  Data Quality  Assurance ............................................................................... 76  
10.1.8.  Source Documents ....................................................................................... 76  
10.1.9.  Study and Site Start and Closure ................................................................. 77  
10.1.10.  Publication  Policy ........................................................................................ 78  
10.2.  Appendix 2: Clinical Laboratory Tests ...................................................................... 79  
10.3.  Appendix 3: AEs and SAEs: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting .......................................................................................... 82  
10.3.1.  Definition of AE .......................................................................................... 82  
10.3.2.  Definition of SAE  ........................................................................................ 84  
10.3.3.  Recording and Follow-Up of AE and/or SAE  ............................................. 85  
10.3.4.  Reporting of SAEs  ...................................................................................... 87  
10.4.  Appendix 4: Contraceptive and Barrier Guidance ..................................................... 89  
10.4.1.  Definitions  ................................................................................................... 89  
Woman of Nonchildbearing Potential (WONCBP) .............................................................. 89  
10.4.2.  Contraception Guidance  .............................................................................. 91  
10.5.  Appendix 5: Graft Versus Host Disease .................................................................... 92  
10.6.  Appendix 6: Cytokine Release Syndrome Scale ....................................................... 95  
10.7.  Appendix 7: Monitoring for and Management of Cytokine Release Syndrome ....... 96  
10.8.  Appendix 8: Endpoint Definitions  ............................................................................. 98  
11. REFERENCES  .................................................................................................................... 105  
 
   
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, [ADDRESS_889618] OF TABLES  
Table 1:  Schedule of Activities –Pre-screening Period and Screening Period (All Cohorts) .... 22  
Table 2:  Schedule of Activities – Treatment --  Period 1 for Patients ≥12 Years of Age (Week 1 
to 14, All Cohorts) ...................................................................................................... 26  
Table 3:  Schedule of Activities – Treatment --  Period 1 for Patients < 12 Years of Age (Week 
1 to 14, All Cohorts) ................................................................................................... 30  
Table 4:  Schedule of Activities: Short- Term Follow -Up--Period 2, All Ages (Weeks 18 to 26, 
All Cohorts) ................................................................................................................ 33  
Table 5:  Protocol- Required Safety Laboratory Tests  ................................................................ 80  
Table 6:  MAGIC Criteria for Staging and Grading of Acute Graft Versus Host Disease ........ 92  
Table 7:  Response Definitions for Acute Graft Versus Host Disease ...................................... 92  
Table 8:  National Institutes of Health Global Severity of Chronic Graft Versus Host Disease 93  
Table 9:  National Institutes of Health Response Determinations for Chronic Graft Versus Host 
Disease  ........................................................................................................................ 93  
Table 10:  ASTCT Consensus Cytokine Release Syndrome Grading Scale ............................... [ADDRESS_889619] OF FIGURES  
Figure 1:  Study Flow Chart ........................................................................................................ 21  
 
 
 
  
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, [ADDRESS_889620] disease 
HBV  Hepatitis B virus  
HC Hemorrhagic cystitis  
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, [ADDRESS_889621]  
PBMC Peripheral blood mononuclear cell 
PML  Progressive multifocal leukoencephalopathy  
PR Partial response  
Q Every  
qPCR Quantitative polymerase chain reaction  
QTL  Quality tolerance limit  
RBC Red blood cell 
SAE  Serious adverse event  
SAP Statistical Analysis Plan  
SoA Schedule of Activities  
 
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, [ADDRESS_889622]  Virus -specific T cell  
WOCBP  Woman of childbearing potential 
WONCBP  Woman of non-childbearing potential 
  
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 16 of 106  
 1. PROTOCOL SUMMARY 
1.1. Synopsis  
Protocol Title: Phase 2, Multicenter, Randomized, Double -Blind, Placebo -Controlled Study to 
Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the 
Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant 
Protocol Number:  P-105-202 
Rationale: 
This is a phase 2 study to evaluate the efficacy and safety of ALVR105 (also known as  Viralym-
M and formerly known as ALVR-105) for the prevention of clinically significant adenovirus 
(AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV) infections and/or disease in patients at high risk for these viruses following allogeneic hematopoietic cell transplant (HCT). In healthy, 
immunocompetent individuals, T cell immunity plays a central role in defending against viruses. 
In HCT recipi[INVESTIGATOR_840], the use of potent immunosuppressive regimens (and subsequent associated immunocompromise) leaves patients susceptible to severe viral infections. In approximately 90% of allogeneic HCT patients, the suppressed immune system allows viruses that were previously in a latent, quiescent state to reactivate and more than 60% of allogeneic HCT patients experience a reactivation of more than one virus, including BKV, CMV, AdV, EBV and HHV-6 ( Hill 2017). Viral infections result in devastating morbidities and have become leading 
etiologies for transplant- related mor tality. There is no approved anti-viral agent that can prevent 
such potentially devastating single and/or multi-virus infection(s) as a single therapy. Some off-label use of antiviral agents is associated with significant toxicities (notably myelosuppression and renal toxicity which might impede their use) and the emergence of drug- resistant  viruses. 
As delay in the recovery of endogenous virus- specific T cells (VST) is clearly associated with 
viral reactivation and disease in these patients, cellular immun otherapy to restore viral- specific 
immunity has been investigated as a potential therapeutic option. The development of Viralym- M for the prevention and preemptive treatment of AdV, BKV, CMV, EBV, HHV-6, and/or JCV infections represents an unmet medical need.  
 
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 17 of 106  
 Objectives and Endpoints: 
Objectives  Endpoints  
Primary  
1. To compare the efficacy of ALVR105  to 
placebo in the proportion of patients with 
clinically significant AdV, BKV, CMV, EBV, HHV-6, and/or JCV infection and/or end- organ disease as determined 
by [CONTACT_10981], blinded Clinical Adjudication Committee (CAC) through Week 14   
1. The proportion of patients with 
clinically significant AdV, BKV, CMV, EBV, HHV-6, and/or JCV infection (defined as infection and/or end-organ disease as determined by 
[CONTACT_10981], blinded CAC) through Week 14 
Secondary  
1. To compare the efficacy of ALVR105  to 
placebo in time to onset of AdV, BKV, CMV, EBV, HHV-
6, and/or JCV viremia 
over [ADDRESS_889623]  
2. To compare the efficacy of ALVR105  to 
placebo in area under the curve (AUC) for cumulative viral load for AdV, BKV, CMV, EBV, HHV-6, and JCV over 14 weeks  
3. To compare the efficacy of ALVR105  to 
placebo in incidence of clinically significant AdV, BKV, CMV, E BV, 
HHV-6, and/or JCV disease (excludes 
asymptomatic viremia) through Week 14 
 
4. To compare the efficacy of ALVR105  to 
placebo in the proportion of patients with 
clearance of AdV, BKV, CMV, EBV, HHV-6, and/or JCV viremia in allogenic HCT patients with detectable viremia prior to the start of treatment  
 
5. To compare the efficacy of ALVR105  to 
placebo in the proportion of patients with clinically significant AdV, BKV, CMV, EBV, HHV-6, and/or JCV infection and/or end- organ disease as determined 
by [CONTACT_10981], blinded CAC through
 
Week 26 (the end of the 12- week safety  
1. Time to onset of AdV, BKV, CMV, EBV, HHV-6, and/or JCV viremia over 14 weeks  
 
 
2. AUC for cumulative viral load for AdV, BKV, CMV, EBV, HHV-6, and JCV over 14 weeks  
 
 
3. Proportion of patients with clinically significant AdV, BKV, CMV, EBV, HHV-6, and/or JCV disease 
(excludes asymptomatic viremia) 
through Week 14 
 
4. Proportion of patients with clearance 
of AdV, BKV, CMV, EBV, HHV-6, 
and/or JCV viremia by [CONTACT_10585] [ADDRESS_889624] patien ts with detectable viremia 
prior to the start of treatment  
 
 
5. Proportion of patients with clinically significant AdV, BKV, CMV, EBV, HHV-6, and/or JCV disease and/or end-organ disease as determined by 
[CONTACT_10981], blinded CAC through Week 26 (the end of the 12-
week safety follow -up period)  
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 18 of 106  
 Objectives  Endpoints  
follow -up period)  
 
6. To compare the efficacy of ALVR105  to 
placebo in reducing hospi[INVESTIGATOR_659646] [ADDRESS_889625] recipi[INVESTIGATOR_659647] 26  
 
8. To compare the efficacy of ALVR105  to 
placebo on patient- reported quality of life 
through Week 26 
9. To assess the safety and tolerability of ALVR105  when administered  to adult 
and pediatric patients at high -risk for 
AdV, BKV, CMV, EBV, HHV-6, and/or JCV following allogeneic HCT   
6. Total number of hospi[INVESTIGATOR_659648], BKV, CMV, EBV, HHV-6, and/or JCV infection or disease through Week 26 
 
7. Proportion of patients with AdV, BKV, CMV, EBV, HHV -6, and/or 
JCV disease -related mortality as 
determined by [CONTACT_10981], blinded CAC through Week [ADDRESS_889626] - 
BMT, EQ -5D- 5L, EQ -5D-Y, and 
EQ-5D-Y Proxy Version 1, through 
Week 26  
9.1. Incidence of overall non- relapse 
related mortality AdV, BKV, CMV, EBV, HHV-6, and/or JCV disease related  mortality  as determined by 
[CONTACT_10981], blinded CAC 
9.2. Severity and incidence of acute GVHD  
9.3. Severity and incidence of chronic GVHD  
9.4. Severity and incidence of cytokine release syndrome 
9.5. Severity and incidence of clinically significant cytopenias 
9.6. Severity and incidence of renal 
dysfunction 
9.7. Effect on measures of  engraftment  
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 19 of 106  
 Objectives  Endpoints  
Exploratory  
1. To assess the development of anti-
viral- specific T  cells 
2. To assess healthcare resource utilization through Week 26 1. Detection of anti - AdV, BKV, CMV, 
EBV, HHV-6, and/or JCV - specific T 
cells through Week 26. 
2.1. Hospi[INVESTIGATOR_659649], BKV, CMV, EBV, HHV-6, 
and/or JCV viremia/disease through Week 26  
2.2. Total days in the ICU through Week 26  
2.3. Proportion of patients requiring mechanical ventilation related to AdV, BKV, CMV, EBV,  HHV-6 
and/or JCV infection or disease through Week 26 
2.4. Duration of anti-viral therapy (foscarnet, ganciclovir, cidofovir or other) due to viremia and/or 
disease through Week  26 
 
For the open-label portion of the study, similar endpoints will be analyzed. Additional details can 
be found in the Statistical Analysis Plan ( SAP). 
  
AlloVir 
Clinical Study Protocol P- 105-202  
Page 22 of 106  
  
1.3. Schedules of Activities  
Table 1: Schedule of Activities –Pre-screening Period and Screening Period (All Cohorts)  
 Pre-screening 
Visita Pre-screening 
Perioda Screening Visitb Screening Periodb 
 
 
Study Week  
NA  
Weekly Visits  Up to 6 weeks 
before Study Drug 
Administration  Weekly after Screening Visit 
until Study Drug 
Administration  
 
 
 
 
Study Day   
 
NA  
 
NA May be from 
Day -42 to Study 
Drug 
Administration 
Day  
 
May be from Day -42 to Study 
Drug Administration Day 
Visit Window (Days) NA ±3 NA ±3 
Study Procedures   
Informed consent/assentc X  X  
I/E criteria  Xd  X  
Demographics   X  
Medical historyd   X  
Documentation of HLA 
typi[INVESTIGATOR_365185]    
X  
Prior and concomitant 
medications including   
 X X 
AlloVir 
Clinical Study Protocol P- 105-202  
Page 23 of 106  
  Pre-screening 
Visita Pre-screening 
Perioda Screening Visitb Screening Periodb 
 
Study Week  
NA  
Weekly Visits  Up to 6 weeks 
before Study Drug 
Administration  Weekly after Screening Visit 
until Study Drug 
Administration  
 
 
 
 
Study Day   
 
NA  
 
NA May be from 
Day -42 to Study 
Drug 
Administration 
Day  
 
May be from Day -42 to Study 
Drug Administration Day 
Visit Window (Days) NA ±3 NA ±[ADDRESS_889627]      
Adverse eventsf   X X 
Complete physical 
examination     
X  
Weight and heightg   X  
Vital signsh   X  
12-lead ECG    X  
Clinical labsi   X  
Pregnancy testj   X  
Testing for HIV, HCV, HBVk   X  
 
AlloVir 
Clinical Study Protocol P- 105-202  
Page 24 of 106  
  
 Pre-screening 
Visita Pre-screening 
Perioda Screening Visitb Screening Periodb 
 
 
Study Week  
NA  
Weekly Visits  Up to 6 weeks 
before Study Drug 
Administration  Weekly after Screening Visit 
until Study Drug 
Administration  
 
 
 
 
Study Day   
 
NA  
 
NA May be from 
Day -42 to Study 
Drug 
Administration 
Day  
 
May be from Day -42 to Study 
Drug Administration Day 
Visit Window (Days) NA ±3 NA ±3 
BKV, AdV, CMV, JCV,  
EBV, and HHV-6 viral loadl  
X  
X  
X  
Xm 
Abbreviations: AdV  = adenovirus; ALT = alanine aminotransferase; AST = aspartate aminotransferase; ; β -HCG = beta human chorionic gonadotropin; BKV  
= BK virus; CBC = complete blood count; CMV = cytomegalovirus; EBV = Epstein- Barr virus; ECG = electrocardiogram; GGT = gamma- 
glutamyltransferase; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency virus; HHV -6 = human herpesvirus 6; 
HLA = human leukocyte antigen; I/E = inclusion and exclusion; JCV = JC virus; LFT = live r function test; NA = not applicable; PBMCs = 
peripheral blood mononuclear cells  
 
Note: Visits may be done via a home health visit as agreed with the Sponsor. Please see the Study Manual for more information. 
 
a Adult p atients and pediatric patients ≥[ADDRESS_889628] and up to 42 (+7) days post -HCT. When this visit occurs during this time period may 
vary by [CONTACT_659666].  
c Prior to conducting any study- related activities, written informed consent/assent to participate in the study must be provided by [CONTACT_5363]/or 
patient’s guardian. The ICF for the pre -screening period is separate from the ICF that is signed at Screening Visit for study participation.  
d  To include CMV s ero status of both patient and HCT dono r 
e The HLA type of the patient and their HCT cell donor (s) will be obtained from the medical record.  
f Adverse events will be monitored and documented from signing of the ICF for study participation until study participation is complete.  
AlloVir 
Clinical Study Protocol P- 105-[ADDRESS_889629] include alkaline phosphatase, bilirubin (total and direct), GGT, AST, and ALT. Urinalysis must be performed. Laboratory safety evaluations 
(hematology, chemistry, and urinalysis) specified in Section 8.4.4 will be performed prior to study therapy initiation. These samples will be sent to the 
appropriate central laboratory( ies) following the procedure(s) described in the study manual(s).  
j For female patients, at Screening a β -HCG blood test will be performed. A urine pregnancy test will also be performed at the site prior to study 
therapy initiation (SoA for Treatment Perio d, Table 2). 
k Serum will be screened for HIV, HBV, and HCV antibodies with reflex nucleic acid testing of plasma. Medical records of previous testing in the last 
3-6 months may be used.  
l Viral loads of BKV, AdV, CMV, JCV, and HHV- 6 in plasma and of EBV in PCMBs will be measured weekly for adult patients and pediatric patients 
≥ [ADDRESS_889630] conditioning during pre -screening period and screening period until treatment assignment, if possible. Pediatric 
patients < [ADDRESS_889631] be available at 
the time of treatment assignment, unless the timing of the Screening Visit is 1 week or less before treatment administration.  Resu lts of central laboratory 
testing for viral load will be used for the purpose of determining eligibility/inclusion.  
m Adult patients and pediatric patients ≥ 12 years old only 
  
AlloVir 
Clinical Study Protocol P- 105-202  
Page 26 of 106  
 Table 2: Schedule of Activities – Treatment -- Period 1 for Patients ≥12 Years of Age (Week 1 to 14, All Cohorts)  
  Treatment Period  
 
 
Time 
Period  Treat 
ment 
Assign 
ment   
Study Drug 
Administration 
Day  
 
 
Wk 1   
 
Wk 
2  
 
Wk 
3  
 
Wk 
4  
 
Wk 
5  
 
Wk 
6  
 
Wk 
7  
 
Wk 
8  
 
Wk 
9  
 
Wk 
10  
 
Wk 
11  
 
Wk 
12  
 
Wk 
13  
 
Wk 
14 
Study Day   1a 8 14 21 28 35 42 49 56 63 70 77 84 91 98 
Visit 
Window 
(Days)    
 
NAb  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±3 
Study 
Procedures                  
Review of 
I/E criteria    
X               
Prior & 
concomitant 
medications 
as well as 
conditioning 
regimen for 
HCT    
 
 
 
 
X   
 
 
 
 
X   
 
 
 
 
X   
 
 
 
 
X   
 
 
 
 
X   
 
 
 
 
X   
 
 
 
 
X   
 
 
 
 
X 
Adverse 
eventsc   
X   
X   
X   
X   
X   
X   
X   
X 
Physical 
examination  
d   
 
X   
 
X   
 
X   
 
X   
 
X   
 
X   
 
X   
 
X 
Weight   X    X    X    X  X 
Vital signse  X  X  X  X  X  X  X  X 
12-lead 
ECGf   
X   
X   
X   
X   
X   
X   
X   
X 
Clinical 
labsg   
X   
X   
X   
X   
X   
X   
X   
X 
Pregnancy 
testh   
X   
X   
X   
X   
X   
X   
X   
  
 
AlloVir 
Clinical Study Protocol P- 105-202  
Page 27 of 106  
   Treatment Period  
 
 
Time 
Period  Treat 
ment  
Assign 
ment   
Study Drug 
Administration 
Day  
 
 
Wk 1   
 
Wk 
2  
 
Wk 
3  
 
Wk 
4  
 
Wk 
5  
 
Wk 
6  
 
Wk 
7  
 
Wk 
8  
 
Wk 
9  
 
Wk 
10  
 
Wk 
11  
 
Wk 
12  
 
Wk 
13  
 
Wk 
14 
Study Day   1a 8 14 21 28 35 42 49 56 63 70 77 84 91 98 
Visit 
Window 
(Days)    
 
NA  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±[ADDRESS_889632] 
infusion 
monitoring
m   
 
X   
 
X   
 
X   
 
X   
 
X   
 
X   
 
X   
Infection 
assessmentn   
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X 
  
AlloVir 
Clinical Study Protocol P- 105-202  
Page 28 of 106  
  
  Treatment Period  
 
 
Time 
Period  Treat 
ment  
Assign 
ment   
Study Drug 
Administration 
Day  
 
 
Wk 1   
 
Wk 
2  
 
Wk 
3  
 
Wk 
4  
 
Wk 
5  
 
Wk 
6  
 
Wk 
7  
 
Wk 
8  
 
Wk 
9  
 
Wk 
10  
 
Wk 
11  
 
Wk 
12  
 
Wk 
13  
 
Wk 
14 
Study Day   1a 8 14 21 28 35 42 49 56 63 70 77 84 91 98 
Visit 
Window 
(Days)    
 
NA  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±3 
Study 
Procedures                  
Quality of 
Life (FACT - 
BMT, EQ - 
5D-5L, EQ- 
5D-Y, EQ- 
5D-Y Proxy 
Version  1)o   
 
 
 
 
X     
 
 
 
 
X     
 
 
 
 
X     
 
 
 
 
X   
 
 
 
 
X 
Abbreviations: AdV  = adenovirus; ALT = alanine aminotransferase; AST = aspartate aminotransferase; ; β -HCG = beta human chorionic gonadotropin; 
BKV = BK virus; CBC = complete blood count; CMV = cytomegalovirus; EBV = Epstein- Barr virus; ECG = electrocardiogram; ET = Early Termination 
Visit; GGT = gamma -glutamyl transferase; GVHD = graft versus host disease; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human 
immunodeficiency virus; HHV -6 = human herpesvirus 6; I/E = inclusion and exclusion; IVIG = intravenous immunoglobulin; JCV = JC virus; LFT = liver 
function test; NA = not applicable; PBMC = peripheral blood mononuclear cell; SoA = Schedule of Activities; VST = virus -specific T cell; Wk = week  
 
Note: Visits may be done via a home health visit as agreed with the Sponsor. Please see the Study Manual for more information.  
 
a Unless noted otherwise, Day [ADDRESS_889633] be performed within 72 hours prior to study treatment administration.  
b Dosing day may be  up to +[ADDRESS_889634], the skin should 
be examined, even if the patient has no complaint, for  evidence of rash/acute skin GVHD.  
e Includes body temperature, blood pressure, heart rate, O [ADDRESS_889635] udy treatment administration and at the end of study or early termination visit, which are listed in the SoA for the Short -
term Follow -up period (Table 3). 
gClinical laboratory assessments collected as part of standard of care may be used to fulfill these requirements. CBC must include differential and LFTs 
AlloVir 
Clinical Study Protocol P- 105-202  
Page 30 of 106  
 Table 3: Schedule of Activities  – Treatment -- Period 1 for Patients < 12 Years of Age (Week 1 to 14, All Cohorts) 
  Treatment 
Period  
 
 
Time 
Period  Treat 
ment  
Assign 
ment   
Study Drug 
Administration 
Day  
 
 
Wk 
1  
 
Wk 
2  
 
Wk 
3  
 
Wk 
4  
 
Wk 
5  
 
Wk 
6  
 
Wk 
7  
 
Wk 
8  
 
Wk 
9  
 
Wk 
10  
 
Wk 
11  
 
Wk 
12  
 
Wk 
13  
 
Wk 
14 
Study Day   1a 8 14 21 28 35 42 49 56 63 70 77 84 91 98 
Visit 
Window 
(Days)    
 
NAb  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±3 
Study 
Procedures                  
Review of I/E 
criteria    
X               
Prior & 
concomitant 
medications as 
well as 
conditioning 
regimen for HCT    
 
 
 
X   
 
 
 
X   
 
 
 
X   
 
 
 
X   
 
 
 
X   
 
 
 
X   
 
 
 
X   
 
 
 
X 
Adverse 
eventsc   
X   
X   
X   
X   
X   
X   
X   
X 
Physical 
examination  
d   
 
X   
 
X   
 
X   
 
X   
 
X   
 
X   
 
X   
 
X 
Weight   X    X    X    X  X 
Vital signse  X  X  X  X  X  X  X  X 
12-lead 
ECGf  
X  X  X  X  X  X  X  X 
Clinical labsg  X  X  X  X  X  X  X  X 
Pregnancy testh  X  X  X  X  X  X  X   
BKV, CMV, 
JCV,  and 
HHV- 6 viral 
loadi  
X  X  X  X  X  X  X X X 
AlloVir 
Clinical Study Protocol P- 105-202  
Page 31 of 106  
   Treatment 
Period  
 
 
Time 
Period  Treat 
ment  
Assign 
ment   
Study Drug 
Administration 
Day  
 
 
Wk 
1  
 
Wk 
2  
 
Wk 
3  
 
Wk 
4  
 
Wk 
5  
 
Wk 
6  
 
Wk 
7  
 
Wk 
8  
 
Wk 
9  
 
Wk 
10  
 
Wk 
11  
 
Wk 
12  
 
Wk 
13  
 
Wk 
14 
Study Day   1a 8 14 21 28 35 42 49 56 63 70 77 84 91 98 
Visit 
Window 
(Days)    
 
NAb  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±5  
 
±3  
 
±[ADDRESS_889636] infusion 
monitoringm  
X  X  X  X  X  X  X   
Infection 
assessmentn  
X X X X X X X X X X X X X X X 
Quality of Life 
(FACT - BMT, 
EQ- 5D-5L, EQ- 
5D-Y, EQ- 
5D-Y Proxy 
Version  1)o  
X    X    X    X  X 
Abbreviations: AdV  = adenovirus; ALT = alanine aminotransferase; AST = aspartate aminotransferase; ; β -HCG = beta human chorionic gonadotropin; BKV = 
BK virus; CBC = complete blood count; CMV = cytomegalovirus; EBV = Epstein- Barr virus; ECG = electrocardiogram; ET = Early T ermination Visit; GGT = 
gamma -glutamyl transferase; GVHD = graft versus host disease; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency virus; 
HHV- 6 = human herpesvirus 6; I/E = inclusion and exclusion; IVIG = intravenous immun oglobulin; JCV = JC virus; LFT = liver function test; NA = not 
AlloVir 
Clinical Study Protocol P- 105-[ADDRESS_889637] also remain on continuous pulse oximetry for ≥ [ADDRESS_889638] -infusion monitoring should be 
completed for  all infusions of study treatment.  
n The infection assessment will be performed for all patients who require either treatment for disease or initiation of preemptive therapy during both the 
primary study period and the follow -up period through Week 26 ( Section 8.3). It is very important to ensure that all procedures, as outlined in the SoA, are 
performed immediately prior to the initiation of treatment of viral diseases or initiation of preemptive therapy (ie, on the day anti- viral therapy is initiated). 
Most importantly, a plasma sample for AdV, BKV, CMV, HHV -6, and JCV and a PBMC sample for EBV for PCR testing at the central laboratory should 
be collected. Patients who develop viral infections will continue to be followed in  the study and complete all remaining visits through Week 26.  
o Assessment of quality of life (using FACT -BMT , EQ-5D-5L, EQ -5D-Y, EQ -5D-Y Proxy Version 1questionnaires, as age -appropriate) should be completed prior to any 
study procedures at this visit.  
 
Table 4: Schedule of Activities: Short -Term Follow -Up--Period 2 , All Ages  (Weeks 18 to 26, All Cohorts)  
Study Week  Week 18  Week 22  Week 26/ETa 
Study Day  126 154 182 
Visit Window (Days)  ±3 ±3 ±3 
Study Procedures  
Prior & concomitant medications  X X X 
Adverse eventsb X X X 
Weight    X 
Vital signs  X X X 
12-lead ECG    X 
Clinical Labs    X 
BKV, AdV, CMV, JCV, and HHV -6 viral loadc  X X 
EBV P CMB sd  X  
Virus -Specific T Cell assessmente X X X 
Infection assessmentf X X X 
Quality of Life (FACT -BMT and EQ -5D-5L, EQ -5D-Y, 
EQ-5D-Y Proxy Version 1)f  
X  
X  
X 
Abbreviations: AdV  = adenovirus; ALT = alanine aminotransferase; AST = aspartate aminotransferase; BKV = BK virus; CBC = complete blood count; 
CMV = cytomegalovirus; EBV = Epstein -Barr virus; ECG = electrocardiogram; ET = Early Termination Visit; GVHD = graft versus host disease;  
HHV- 6 = human herpesvirus 6; JCV = JC virus; LFT = liver function test; PBMCs = peripheral blood mononuclear cells  
Note: Visits may be done via a home health visit as agreed with the Sponsor. Please see the Study Manual for more information. 
a The Early Termination Visit will be performed for all patients who are prematurely discontinued from the study up to Week 26.  It is very important to 
ensure that all procedures are performed in such patients at this visit prior to discontinuing the patient  from the trial. Most importantly, a plasma sample 
for AdV, BKV, CMV, HHV- 6, and JCV and a PCMB sample for EBV for PCR testing at the central laboratory should be collected at this visit.  
AlloVir 
Clinical Study Protocol P- 105-[ADDRESS_889639] of care the rapy (see Section 8.3 ). 
d Patient peripheral  blood mononuclea r cells will be assessed  for the presence of virus -reactive T cells using enzyme -linked  immunospot.  
e The infection assessment will be performed for all patients who require either treatment for disease or initiation of preemptive therapy during both the 
primary study period and the follow -up period through Week 26 ( Section 8.3) . It is very important to ensure that all procedures, as outlined in the SoA, are 
performed immediately prior to the initiation of treatment of viral diseases or initiation of preemptive therapy (ie, on the day anti -viral therapy is initiated). 
Most importantly, a plasma sample for AdV, BKV, CMV, HHV -6, and JCV and a PCMB sample for EBV for PCR testing at the central laboratory should 
be collected. After developi[INVESTIGATOR_89994], such patients will continue to be followed in the study and complete all remaining visits through Week 26.  
f Assessment of quality of life (using FACT -BMT, EQ -5D-5L, EQ -5D-Y, and EQ -5D-Y Proxy Version 1questionnaires, as age -appropriate) should be 
completed prior to any study procedures at this visit.  
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 35 of 106  
 2. INTRODUCTION 
ALVR105 (also known as Viralym-M and formerly known as ALVR-105) is a cellular therapy 
consisting of third -party, multivirus -specific T cells with specificity for adenovirus [AdV], BK 
virus [BKV], JC virus [JCV], human herpesvirus 6 [HHV- 6], Epstein-Barr virus [EBV], and cytomegalovirus [CMV] in   
AlloVir is developi[INVESTIGATOR_659650]105  (also known as ALVR105, formerly ALVR-105), a novel 
multivirus -specific cellular therapy, to treat or prevent a number of serious, virus- associated causes 
of morbidity and mortality after allogeneic HCT, including those caused by [CONTACT_659667] (and the related polyomavirus JCV), CMV, HHV-6, EBV, and AdV. 
2.1. Study Rationale 
This is a phase 2 study to evaluate the efficacy and safety of ALVR105  for the prevention of 
clinically significant adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein- Barr 
virus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV) infections and/or disease in patients at high risk for these viruses following allogeneic hematopoietic cell transplant (HCT). In healthy, immunocompetent individuals, T cell immunity plays a central role in defending against viruses. In HCT recipi[INVESTIGATOR_840], the use of potent immunosuppressive regimens (and subsequent associated immunocomp romise) leaves patients susceptible to severe viral infections. In 
approximately 90% of allogeneic HCT patients, the suppressed immune system allows viruses that were previously in a latent, quiescent state to reactivate and more than 60% of allogeneic HCT patients experience a reactivation of more than one virus, including BKV, CMV, AdV, EBV and HHV-6 ( Hill 2017). Viral infections result in devastating morbidities and have become leading 
etiologies for transplant- related mor tality. There is no approved anti-viral agent that can prevent 
such potentially devastating single and/or multi-virus infection(s) as a single therapy. Some off-label use of antiviral agents is associated with significant toxicities (notably myelosuppression and renal toxicity which might impede their use) and the emergence of drug- resistant viruses.  
As delay in the recovery of endogenous virus- specific T cells (VST) is clearly associated with viral 
reactivation and disease in these patients, cellular immu notherapy to restore viral- specific 
immunity has been investigated as a potential therapeutic option. The development of ALVR105  
for the prevention and preemptive treatment of AdV, BKV, CMV, EBV, HHV-6, and/or JCV infections represents an unmet medical need. 
2.2. Background 
During the period of immune recovery after allogeneic HCT, viral infections and reactivations, 
which are normally controlled by T cell immunity, are an important cause of morbidity  and 
mortality. The risk for infection is dictated by a number of factors, including the degree of immunosuppression and the immune status of the donor. Reactivation of latent viruses such as CMV and BKV, or primary infection with a virus such as AdV, has become increasingly prominent. In a study at a large US HCT center, in approximately 90% of allogeneic HCT patients, the suppressed immune system allows viruses that were previously in a latent, quiescent state to reactivate and more than 60% of allogeneic HCT patients experience a reactivation of more than one virus, including BKV, CMV, AdV, EBV and HHV-6 ( Hill 2017). In another recent study of 
infections following haploidentical allogeneic HCT, Slade, et al documented that 72% of patients 

AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, [ADDRESS_889640] one severe viral infectio n (Slade 2017). Fifteen percent of patients developed 
CMV infection despi[INVESTIGATOR_430903], and 19% developed BK virus- associated  –hemorrhagic 
cystitis. One of [ADDRESS_889641] ( Sedláček 2019). Progression to AdV disease is associated with significant 
morbidity and mortality rates of up to 50% ( Zecca 2019 ). Similarly, Mulanovich and colleagues 
(2011) reported that, among patients receiving either cord blood or T- cell depleted transplants, viral 
infections were frequent and the most common cause of death in both groups. Even among T cell-
replete transplants using the post-cyclophosphamide protocol, Crocchiolo ( 2015) reported the 
incidence of viral infections to be 70%, with CMV and BKV being the most frequent and the most clinically threatening etiologies. The increased risk of mortality in the first [ADDRESS_889642]-transplant was approximately 18 times greater for patients with a CMV viral load  ≥250 IU/ml ( Green  2016).  
2.2.1. Overview of Nonclinical Studies with  ALVR105  
Consistent with guidance from the [LOCATION_002] Food and Drug Administration (FDA), AlloVir proceeded to clinical studies following completion of in vitro studies. No nonclinical animal pharmacology, pharmacokinetic, or toxicology studies of ALVR105  have been conducted  or are 
planned. For additional information related to nonclinical studies with ALVR105 , see the 
Investigator’s Brochure. 
2.2.2. Overview of Clinical Studies with Virus -Specific T  Cells  
[IP_ADDRESS]. Results of the CHARMS Study with Third Party -Derived Multivirus -Specific T 
Cells,  ALVR105  
To investigate the safety and clinical efficacy of ALVR105, a multivirus -specific T cell product 
reactive for BKV, AdV, HHV-6, EBV, and CMV generated from third-party, healthy, eligible 
donors, a Phase 1/2a clinical study was conducted in recipi[INVESTIGATOR_659651]- 
refractory infections with ≥ 1 of the 5 viruses targeted by [CONTACT_659668]105  (Tzannou, 2017) . In this study, 
patients received a sin gle IV infusion of 2× 10
7 partially HLA -matched ALVR105  cells/m2, with the 
option to receive a second infusion after 4 weeks (actual range 14 days to >6 weeks) and additional 
infusions at biweekly intervals thereafter. Therapy with standard antiviral medications could be continued at the discretion of the treating phys ician ( Tzannou, 2017 ). 
A total of [ADDRESS_889643] were infused with ALVR105  cell lines matched at 1 to 6 HLA antigens; 54 of these patients completed study 
treatment and t he initial 28 -day safety follow-up (the first 38 patients to complete the study are 
reported in Tzannou et al, 2017. Of the 71 total infections treated, 25 (35.2%) infections were BKV and 24 (33.8%) infections were CMV. Of the 58 patients who were treated (one of whom had 2 courses of treatment), 48 patients were treated for a single virus, 10 patients were treated for 2 viral infections, and 1 patient was treated for infections by 3 different viruses. 
All infusions were well tolerated. None of the patients developed cytokine release syndrome 
(CRS). In the weeks after infusion, 1 patient developed recurrent Grade 3 gastrointestinal (GI) GVHD following rapid systemic corticosteroid taper, and 8 patients developed recurrent (n = 4) or de novo (n = 4) Grade 1 to 2 skin GVHD, which resolved with the administration of topi[INVESTIGATOR_12969] (n = 7) and reinitiation of systemic corticosteroids after taper (n = 1). Between 3 and 6 months after infusion, 2 patients experienced a flare of upper GI GVHD, which resolved after a brief systemic corticosteroid course.  
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 37 of 106  
 Fifty -four (93%) of 58 evaluable patients had either a partial or complete clinical or virological 
response (either PR [defined as >50% reduction in viral load, or >50% improvement of clinical 
signs and symptoms] or CR [defined as return of the viral load to the normal range and resolution of clinical signs and/or symptoms]); no response was observed in 2 patients with AdV, and 1 each with CMV and HHV-6. Of note, all 23 patients with BKV-associated hemorrhagic cystitis (HC), 2 of 3 patients with CMV colitis, the patient with CMV encephalitis (n = 1), the patients with AdV enteritis (n = 1) and AdV HC (n = 1), and [ADDRESS_889644] responders (CR or PR), a post-infusion increase in the frequency of circulating VSTs was detected.  
In addition to patients with post- HCT CMV, EBV, AdV, BKV, and HHV-6- associated infections, 
patients with JCV infections were also enrolled in this Phase 1/[ADDRESS_889645] -party  BKV- specific T cel ls could 
produce similar results in 3 immunosuppressed patients with progressive multifocal leukoencephalopathy (PML). Post-infusion, [ADDRESS_889646] patient had a reduction in JC viral load and stabilization of symptoms ( Muftuoglu 2018) Given these promising results in the context of a 
complete lack of proven antiviral medications effective against JCV and the potentially devastating comp lications associated with JCV, patients with JCV infection will be included in the Phase 3 
study. 
2.3. Benefit/Risk Assessment  
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events (AEs) of ALVR105  may be found in the Investigator’s Brochure. 
2.3.1. Potential  Benefits  
A serious unmet medical need exists for patients experiencing viral infections and diseases such as AdV, BKV, CMV, EBV, HHV-6, and JCV following allogeneic HCT. Viral diseases post HCT are one of the highest causes of non-relapse morbidity and mortality in the post-transplant period. Despi[INVESTIGATOR_659652]- viral therapi[INVESTIGATOR_014], there is a major medical need  due to 1) 
emergent resistance to therapy, 2) toxicity of available anti -virals, and 3) a subset of viruses: AdV, 
BKV, HHV-6, EBV, and JCV for which there are no approved and/or clearly effective therapi[INVESTIGATOR_014]. The CHARMS study and other related clinical studies strongly suggest that ALVR105  is a safe and 
effective broad -spectrum therapy to treat commonly observed and severe virus- associated diseases 
after allogenic HCT. The results of these studies provide preliminary evidence of ALVR105 's 
efficacy for multiple opportunistic viral infections in allogeneic HCT recipi[INVESTIGATOR_840], and its safety profile has the potential to be significantly better than that of standard, and inadequately effective, currently available antiviral therapy.  
2.3.2. Potential  Risks  
ALVR105  primarily targets cells infected with AdV, BKV (and/or JCV), CMV, EBV, and/or 
HHV-6. The main risks of administration are inflammation at sites of existing disease or GVHD due to cross-reactivity with the recipi[INVESTIGATOR_841]’s HLA antigens. Adverse events attributable to virus- specific T cell administration may potentially occur in a small percentage of th e treated  population. 
These can include both hematologic and non- hematologic effects, as reported in the CHARMS 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, [ADDRESS_889647] in 
patients  who receive methylprednisolone in doses ≥ 1 mg/kg/day. Therefore, if patients develop 
severe inflammatory reactions thought to be attributable to ALVR105 , a therapeutic option is to 
administer methylprednisolone (1 to 2 mg/kg/day). In patients who develop skin rash or skin 
GVHD, excellent responses have been noted with the administration of topi[INVESTIGATOR_8826]. 
As with other biological therapi[INVESTIGATOR_659653], the side effects of ALVR105  infusion 
include allergic reactions (anaphylaxis), decreased oxygenation, nausea/vomiting, arrhythmia, and 
hypotension. 
A detailed breakdown of the timepoints and blood volumes to be collected during the cour se of this 
study is provided in the Laboratory Manual. In order to minimize the volume of blood collected during the study trial, the blood volume of 
individual samples has been reduced to the maximum extent feasible wherever possible. This has been performed in a manner that is expected to maintain the scientific integrity of the study and related data, while minimizing the risks to the patients.  
In order to minimize the volume of blood collected during the study, especially for pediatric patients, the blood volume of individual samples has been reduced to the maximum extent feasible wherever possible. For pediatric patients < 12 years of age, collection of blood samples for the evaluation of viral load for all six viruses ( AdV, BKV, CMV, EBV, and/or HHV-6, and JCV) is  
limited to every other week  and blood volume is sufficient for testing only AdV viremia in the 
other weeks . Pediatric patients also do not participate in pre-screening blood samples. This 
reduction in volume of blood collection has been done i n a manner that is expected to maintain the 
scientific integrity of the study while minimizing the risks to patients.  For maximum blood draw 
volumes, see the Laboratory Manual. 
For the collection of other study- related material from the patients, there are no invasive procedures 
that are required for the study conduct beyond those that are used as part of the routine and 
standard clinical care of patients undergoing allogeneic HCT. 
 
 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 39 of 106  
 3. OBJECTIVES AND  ENDPOINTS  
Objectives  Endpoints  
Primary  
1. To compare the efficacy of ALVR105  
to placebo in the proportion of patients 
with clinically significant AdV, BKV, CMV, EBV, HHV-6, and/or JCV infection and/or end- organ disease as 
determined by [CONTACT_10981], blinded Clinical Adjudication Committee (CA C) through Week 14  
1. The proportion of patients with 
clinically significant AdV, BKV, CMV, EBV, HHV-6, and/or JCV infection (defined as infection and/or end-organ disease as determined by 
[CONTACT_10981], blinded CAC) through Week 14 
Secondary  
1. To compare the efficacy of ALVR105  to placebo in time to onset 
of AdV, BKV, CMV,  EBV, HHV-6, 
and/or JCV viremia over [ADDRESS_889648]  
2. To compare the efficacy of ALVR105  to placebo in area under 
the curve (AUC) fo r cumulative 
viral load for AdV, BKV, CMV, EBV, HHV-6, and JCV over 14 weeks  
3. To compare the efficacy of ALVR105  
to placebo in incidence of clinically significant AdV, BKV, CMV, EBV, 
HHV-6, and/or JCV disease (excludes asymptomatic viremia) through Week 14 
4. To compare the efficacy of ALVR105  
to placebo in the proportion of patients with clearance of AdV, BKV, CMV, EBV, HHV-6, and/or JCV viremia in allogeneic HCT patients with detectable viremia prior to the start of  
treatment   
1. Time to onset of AdV, BKV, CM V, 
EBV, HHV-6, and/or JCV viremia over 14 weeks  
 
 
 
2. AUC for cumulative viral load for AdV, BKV, CMV, EBV, HHV- 6, and 
JCV over 14 weeks  
 
 
 
3. Proportion of patients with clinically significant AdV, BKV, CMV, EBV, HHV-6, and/or JCV disease (excludes asymptomatic viremia) 
through Week 14 
 
4. Proportion of patients with clearance 
of AdV, BKV, CMV, EBV, HHV-6, 
and/or JCV viremia by [CONTACT_10585] [ADDRESS_889649] patients with detectable viremia prior to the start of treatment  
5. To compare the efficacy of ALVR105  
to placebo in the proportion of patients with clinically significant AdV, BKV, 
CMV, EBV, HHV -6, and/or JCV 5. Proportion of patients with clinically significant AdV, BKV, CMV, EBV, HHV-6, and/or JCV disease and/or 
end-organ disease as determined by [CONTACT_659669] P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 40 of 106  
 Objectives  Endpoints  
infection and/or end -organ disease as 
determined by [CONTACT_10981], blinded 
CAC through Week 26 (the end of the 
12-week safety follow - up period) 
6. To compare the efficacy of ALVR105  
to placebo in reducing hospi[INVESTIGATOR_659654] [ADDRESS_889650] recipi[INVESTIGATOR_659647] 26 
 
8. To compare the efficacy of 
ALVR105  to placebo on patient- 
reported quality of life through Week 
26 
 
9. To assess the safety and tolerability of ALVR105  when administered to adult 
and pediatric patients at high -risk for 
AdV, BKV, CMV, EBV, HHV-6, and/or JCV following allogeneic HCT  independent, blinded CAC through 
Week 26 (the end of the 12- week safety 
follow- up period) 
 
6. Total number of hospi[INVESTIGATOR_659648], BKV, CMV,  EBV, HHV-6, 
and/or JCV infection or disease through Week 26 
7. Proportion of patients with AdV, BKV, CMV, EBV,  HHV -6, and/or 
JCV disease -related mortality as 
determined by [CONTACT_10981], blinded CAC  through Week [ADDRESS_889651] - 
BMT, EQ -5D- 5L, EQ -5D-Y, and EQ-
5D-Y Proxy Version 1, through Week 26 
 
 
9.1. Incidence of overall non- relapse 
related mortality AdV, BKV, CMV, EBV, HHV-6, and/or JCV disease related  mortality  as determined by [CONTACT_64693], blinded CAC 
9.2. Severity and incidence of acute GVHD  
9.3. Severity and incidence of chronic GVHD  
9.4. Severity and incidence of cytokine release syndrome 
9.5. Severity and incidence of clinically significant cytopenias 
9.6. Severity and incidence of renal dysfunction 
9.7. Effect on measures of  engraftment  
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 41 of 106  
 Objectives  Endpoints  
Exploratory  
1. To assess the development of 
antiviral- specific T  cells 
2. To assess healthcare resource utilization through Week 26 1. Detection of anti - AdV, BKV, CMV, 
EBV, HHV-6, and/or JCV - specific T cells through Week 26. 
2.1. Hospi[INVESTIGATOR_659649], BKV, CMV, EBV,  HHV- 6, 
and/or JCV viremia/disease through Week  26 
2.2. Total days in the ICU through Week 26  
2.3. Proportion of patients requiring mechanical ventilation related to AdV, BKV, CMV, EBV,  HHV-6 
and/or JCV infection or disease through Week 26 
2.4. Duration of anti-viral therapy (foscarnet, ganciclovir, cidofovir or other) due to viremia and/or disease through Week 26 
 For the open-label portion of the study, similar endpoints will be analyzed. Additional details can 
be found in the Statistical Analysis Plan ( SAP). 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 45 of 106  
 actual doses administered in the CHARMS study demonstrated that, on average, patients who 
weighed ≥ 40 kg received  per infusion (n = 45). For patients <40 kg, the dose will 
be    
4.4. End of Study De
finition  
The end of the study (“study completion”) is defined as the date of the last protocol- specified 
visit/assessment (including telephone contact) for the last patient in the study. 
A participant is considered to have completed the study if he/she has completed all phases of the 
study including the Week [ADDRESS_889652] a follow up telephone call at approximately 52 weeks (12 months) 
after the end of study visit to collect mortality data.  
4.4.1. Meals and Dietary  Restrictions  
This section is not applicable. 
 

AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, [ADDRESS_889653] meet all the following criteria in order to be eligible to participate in the study: 
 
Age 
1. Be ≥1 year of age at the day of  screening. 
Type of Participant and Disease Characteristics  
 
 
 
 
 
 
 
For OL Cohort 
4. May meet viremia criterion for either Cohort A or Cohort B 
For OL Cohort,  
5. Be within 15 and 42 (+7)  days of receiving a first allogeneic HCT at the time of 
treatment assignment and have demonstrated engraftment with an absolute 
neutrophil count >500/µL.  
6. High -risk: Patients meeting one or more of the following criteria at the time of  treatment 
assignment: 
o Human leukocyte antigen (HLA)- related (sibling) donor with at least one mismatch 
at one of the following three HLA-ge ne loci: HLA -A, -B or - DR 
o Haploidentical  donor 
o Unrelated donor with at least one mismatch at one of the following four HLA- gene 
loci: HLA -A, -B, - C and  -DRB1  
o Use of umbilical cord blood as stem cell source 
o Ex vivo graft manipulation resulting in T cell depletion  
o Lymphocyte count <180/mm3 and/or cluster  of differentiation  4 (CD4) T cell count 
<50/mm3  
 
Sex 

AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 47 of 106  
 7. Male and/or  female  
a. Male participants: 
Male participants are eligible to participate if they agree to the following during the 
study intervention period and for at least [ADDRESS_889654] dose of study intervention: 
• Refrain from donating s perm PLUS,  either : 
• Be abstinent from heterosexual intercourse as their preferred and usual 
lifestyle (abstinent on a long term and persistent bas is) and agree to remain  
abstinent 
OR 
• Must agree to use contraception /barrier as detailed  below 
• Agree to use a male condom and should also be advised of the benefit for a 
female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant 
b. Female participants: 
• A female participant is eligible to participate if she is not pregnant 
or breastfeeding, and 1 of the following conditions applies:  
• Is a woman of non-childbearing potential (WONCBP) as defined 
in Section  10.4.1  
OR 
• Is a WOCBP and using an acceptable contraceptive method as described in 
Section 10.4.[ADDRESS_889655] dose of study intervention. The Investigator should evaluate the 
potential for contraceptive method failure (eg, noncompliance, recently initiated) in relationship to the first dose of study intervention. 
• A WOCBP must have a negative highly sensitive serum pregnancy test 
within [ADDRESS_889656] dose of study intervention, see Section  8.4.5.  
• Additional requirements for pregnancy testing during and after 
study intervention are located in Section  8.4.5. 
• The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected  pregnancy.  
 
 
Informed Consent  
8. Willing and able to provide written informed consent as described in Section 10.1.3 to 
participate in the study, or a parent or legal guardian is willing and able to provide written informed consent and the potential pediatric patient is able to provide assent in a 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, [ADDRESS_889657] (IRB) and local regulations 
 
5.2. Exclusion Criteria  
Patients  who meet any of the following criteria will be excluded from participation in the study: 
Medical Conditions  
1. Has a history of AdV, BKV, CMV, EBV, HHV-6, and/or JCV end- organ disease 
within 6 months prior to treatment assignment 
2. Has evidence of AdV, BKV, CMV, EBV, HHV-6, and/or JCV viremia for more 
than 3 viruses, from a central or local laboratory at any time during Screening prior to treatment assignment 
3. Evidence of active Grade >2 acute GVHD (for additional information on acute 
GVHD grading and severity, see Appendix 5 [ Section 10.5] or CRS
 Appendix 6 
[Section 10.6 ], respectively).  
4. Presence of non -minor uncontrolled or progressive bacterial or fungal infections (ie, 
evidence of bacteremia, fungemia, disseminated, and/or organ-specific infection not 
well controlled by [CONTACT_594902][INVESTIGATOR_014])  
5. Presence of progressive, uncontrolled viral infections with evidence of end organ disease  
6. Known history or current (suspected) diagnosis requiring treatment of CRS  associated with the administration of peptides, proteins, and/or 
antibodies 
7. Evidence of encephalopathy at screening  
8. Relapse of primary malignancy other than minimal residual disease.  
 
Prior/Concomitant Therapy  
9. Donor lymphocyte infusion performed within 21 days prior to randomization 
10. Received within 7 days prior to treatment assignment any of the following: ganciclovir, valganciclovir, foscarnet, acyclovir (at doses >3200 mg PO per day or >25 mg/kg IV per day), valacyclovir (at doses >3000 mg PO per day), famciclovir (at doses >1500 mg PO per day) 
11. Received any investigational antiviral agent/biologic therapy within 30 days prior to screening or plans to receive during the study any of the following: cidofovir, CMV hyper-immune globulin, or any investigational CMV antiviral agent/biologic therapy. 
12. Ongoing therapy with high- dose systemic corticosteroids (ie, prednisone equivalent dose 
>0.5 mg/kg/day) within 7 days prior to screening 
13. Prior therapy with antithymocyte globulin, alemtuzumab (Campath-1H), or other 
immunosuppressive T cell-targeted monoclonal antibodies within 28 days of treatme nt 
assignment 
14. Receipt of mechanical ventilation of any type, within 1 month prior to the 
administration of ALVR105  (unless related to airway  control) 
15. Undergoing dialysis at any time during the screening period 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 49 of 106  
  
Prior/Concurrent Clinical Study Experience 
16. Received a previous allogeneic HCT (Note: Receipt of a previous autologous HCT 
is acceptable)  
17. Receipt of another investigational antiviral vaccine or treatment during the study or within 28 days prior to treatment assignment or study treatment a dministration  
Diagnostic assessments 
18. Aspartate aminotransferase or alanine aminotransferase serum levels >5 × the upper limit of normal (ULN) or direct bilirubin serum levels >2 × the ULN reference per central laboratory.  
19. Presence of any progressive, uncontrolled viral infections (ie, evidence of viremia, dissemination, and/or organ-specific infection not well controlled by [CONTACT_594902][INVESTIGATOR_014]) not targeted by [CONTACT_659668]105 . 
Other Exclusions  
20. Pregnant, breastfeeding, or planning to become pregnant during the study 
21. Has a history or current evidence of any condition, therapy, lab abnormality, or other 
circumstance that might confound the results of the study, interfere with the patient's 
participation for the full duration of the study, or would be put at undue risk as judged by [CONTACT_737], such that it is not in the best interest of the patient to participate in this study 
5.3. Lifestyle Restrictions  
This section is not applicable. 
5.3.1. Caffeine, Alcohol, and Tobacco  
This section  is not applicable. 
5.3.2. Activity  
This sec tion is not applicable. 
5.4. Screen Failures  
Screen  failures are defined as participants who consent to participate in the clinical study but are 
not randomized into the clinical study. A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure participants to meet the Consolidated Standards of Reporting Trials publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any serious adverse events (SAEs) . 
Individuals who do not meet the criteria for participation in this study (screen failure) may be rescreened in consultation with the Medical Monitor. 
 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, [ADDRESS_889658] dose of ALVR105  (or placebo) after Week 14. 
Patients will continue in the study for evaluation of safety, efficacy, and other endpoints after Week 
14 for an additional 3 months (through Week 26).  
6.6. Continued Access to Study Intervention after the End of the Study  
No further treatment will be provided after the last dose of ALVR105  (or placebo) after Week 14 . 
However, patients will continue in the study for evaluation of safety, efficacy, and other endpoints for an additional 12 wee ks (3 months). 
6.7. Treatment of Overdose  
For this study, any dose of ALVR105  greater than  any dose over the IRT assigned dose (2x10
7 for 
patients <  40 kg or 4× 107 cells for patients ≥ 40 kg) within a 24-hour period (±1 hour) will be 
considered an overdose. 
As there is no antidote, the Sponsor does not recommend specific treatment for an overdose. In the 
event of an overdose, the Investigator should: 
• Contact [CONTACT_180818].  
• Evaluate the patient to determine, in consultation with the Medical Monitor, whether study treatment should be interrupted or whether the dose should be reduced.  
• Closely monitor the patient for any AE/SAE and laboratory abnormalities until the next dosing day. 
• Document the quantity of the excess dose as well as the duration of the overdose. 
6.8. Concomitant Therapy 
Clinically available (ie, not investigational) antiviral agents prescribed for other infections, such as foscarnet  and ganciclovir to treat CMV, are allowed. Data on their use will be collected along with 
other concomitant medications. 
6.8.1. Excluded Medications and/or  Procedures  
All patients  may receive available supportive therapy with approved treatments. Investigators 
should try to maintain stable treatment to the extent possible.   
Receipt  of other investigational antiviral treatments (eg, brincidofovir or anti-BK virus monoclonal 
antibodies) within 28 days prior to randomization and throughout the duration of the study is 
prohibited. 
Treatment with supportive regimen therapi[INVESTIGATOR_014], other intravesicular agents for the control of bleeding 
(including, but not limited to, aminocaproic acid), antispasmodics, treatment for pain control (including opi[INVESTIGATOR_2438]), and blood product transfusion support are permitted. Analgesic use will be collected on a daily basis. Clinically available (ie, not investigational) antiviral agents prescribed for other infections are allowed. Use of cidofovir or brincidofovir (eg, for the treatment of AdV) must be discussed with the Medical Monitor prior to initiation. All instances of the use of any antiviral agents during the study will be recorded in the eCRF (including the drug name, dose, and 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 55 of 106  
 duration of treatment). 
T cell ablative therapi[INVESTIGATOR_014], such as antit hymocyte globulin, alemtuzumab (Campath-1H), or other 
immunosuppressive T cell-targeted monoclonal antibodies, are prohibited during the course of the 
study. Daily doses of corticosteroids exceeding 0.5 mg/kg prednisone (or equivalent) are prohibited during the course of the study. Should patients require medically a higher dose of steroids, no further study drug will be administered until the steroids are tapered to a dose equivalent of 0.5 mg/kg prednisone (or equivalent) or less. 
6.8.2. Restricted Medications and/or Procedures  
[IP_ADDRESS]. Supportive  care  
The following supportive care measures are permitted: 
• Analgesics  
• Narcotics  
• IV hydration 
• Antispasmodics 
• Transfusion of red blood cells (RBCs)  
• Transfusion of platelets  
• Transfusion of fresh frozen plasma  
All supportive care measures must be documented in the patient study records and the eCRF. 6.8.3. Documentation of Prior and Concomitant Medication Use 
All medications, including GVHD prophylaxis, used within 30 days before screening will be 
recorded. All concomitant  medications and concurrent therapi[INVESTIGATOR_659655] ( Section 1.3). Dose, route, unit frequency of administration, indication for administration, 
and dates of medication will also be captured in source documents and on the appropriate eCRF. 
6.8.4. Rescue Medication  
This section is not applicable. 
 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 56 of 106  
 7. DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL  
7.1. Disco ntinuation of Study Intervention 
The following criteria do not necessitate withdrawal from the study, but do render the patient 
ineligible  to receive any additional infusions of study treatment: 
1. Development of irreversible, life-threatening, Grade [ADDRESS_889659] ALVR105  dose that is 
considered related to study treatment administration. If this occurs, the patient’s to xicities 
will be followed until resolution or until the patient’s participation in the study  ends. 
2. Receipt of any other hematopoietic stem cell  product. 
3. Receipt of therapy for relapse of the patient’s primary  malignancy. 
4. Occurrence of Grade 3 or 4 CRS  that persists beyond 72 hours. If this occurs,  the patient’s 
toxicities will be followed until resolution or until the patient’s participation in the study ends. 
If any of the above criteria are met, every effort should be made to keep the patient in the study and continue follow-up. 
7.1.1. Temporary  Discontinuation 
Temporary discontinuation will be allowed only if discussed with and approved by [CONTACT_22955]. 
7.1.2. Rechallenge  
This section  is not applicable. 
7.2. Participant Discontinuation/Withdrawal from the Study  
Participation  of a patient in this clinical study may be discontinued for any of the following 
reasons:  
• The patient withdraws consent  
• The patient requests discontinuation from the study for any reason  
• Occurrence of any medical condition or circumstance that exposes the patient to 
substantial risk and/or does not allow the patient to adhere to the requirements of 
the protocol 
• Any SAE, clinically significant AE, severe laboratory abnormality, intercurrent illness, 
or other medical condition that indicates to the Investigator that continued participation is not in the best interest of the  patient  
• Pregnancy  
• Requirement for prohibited concomitant medication  
• Patient failure to comply with protocol requirements or study- related  procedures  
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 57 of 106  
 • Termination of the study by [CONTACT_659670], the Sponsor may retain 
and continue to use any data collected before such a withdrawal of consent. 
If a participa nt withdraws from the study, he/she may request destruction of any samples taken  and 
not tested, and the Investigator must document this in the site study records. Patients who are discontinued from the study for any reason will not be replaced. Patients who 
discontinue the study early, should have the procedures scheduled for the Week 26/ET visit completed at the time of discontinuation from the study. The reason for patient withdrawal must be documented in the eCRF. 
7.3. Early Termination 
The ET Visit will be performed for all patients who are prematurely discontinued up to Week 26 
from  the study; however, patients who decide only to discontinue therapy early will continue to 
complete trial procedures as per protocol. It is very important to ensure that all procedures, as outlined in the SoA ET visit, are performed in such patients at this visit prior to discontinuing the patient from the trial. Most importantly, a plasma sample for AdV, BKV, CMV, HHV -6, and JCV 
and a PCMB sample for EBV for PCR testing at the central laboratory should be collected at this visit.  
7.4. Lost to Follow up 
A participant  will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298]. 
The following actions must be taken if a participant fails to return to the clinic for a required  study 
visit:  
• The site must attempt to contact [CONTACT_659671]/or should continue in the study. 
• Before a participant is deemed lost to follow up, the Investigator or designee must make every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, if necessary, a certified letter to the participant’s last known mailing address or local equivalent methods). These contact [CONTACT_13140]’s medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have withdrawn from the study. 
Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 1 in Section 10.1.9. 
 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 58 of 106  
 8. STUDY ASSESSMENTS AND  PROCEDURES  
• Study procedures and their timing are summarized in the SoA. Protocol waivers 
or exemptions are not allowed.  
• Immediate safety concerns should be discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue study intervention. 
• Adherence to the study design requirements, including those specified in the SoA, 
is essential and required for study conduct. 
• All screening evaluations must be completed and r eviewed to confirm that potential 
participants meet all eligibility criteria. The Investigator will maintain a screening log 
to record details of all participants screened and to confirm eligibility or record reasons for screening failure, as  applicable.  
• Procedures conducted as part of the participant’s routine clinical management (eg, blood count) and obtained before signing of the informed consent form (ICF) may be utilized for screening or baseline purposes provided the procedures met the protocol-specif ied criteria and were performed within the time frame defined in the  SoA.  
• Results (eg, Safety/Laboratory/analyte) that could unblind the study will not be reported to investigative sites or other blinded personnel until the study has been unblinded. 
• The am ount of blood collected from each adult (≥18 years) and pediatric patient over 
the duration of the study are described in the Laboratory Manual. The maximum amount of blood collected, including any extra assessments that may be required, will not exceed
 10.5 mL/kg or 550 mL, whichever is smaller, over any eight week period for adult 
patients.  
• For pediatric patients, blood sampling requirements for the study have been minimized by [CONTACT_659672] (where possible), and by [CONTACT_659673].  
• Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the  samples.  
8.1. Study Periods  
8.1.1. Pre-screening visit  (optional) 
A pre -screening visit will be completed if possible at least [ADDRESS_889660] and within 42 (+7)  
days after transplantation. Patients will have plasma samples tested for AdV,  BKV, CMV, HHV-6, 
and JCV viremia and 
PBMC s for EBV viremia using PCR assays weekly during the screening 
period. Patients should be tested at the first assessment during Screening by [CONTACT_659674], BKV, CMV, EBV, HHV-6, and JCV viremia using PCR assays for each virus. Patients 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 60 of 106  
 the lower limit of quantification (LLOQ) and complete resolution of clinical signs and symptoms 
as determined by [CONTACT_659675] (see Appendix 7, Section 10.7). 
8.2.4. Quality of Life 
Quality of life will be measured using the FACT -BMT and the age-appropriate version of the EQ-
5D at times indicated in S ection 1.3. The FACT -BMT was designed to measure the QoL in patients 
undergoing bone marrow transplantation. It combines the general Functional Assessment of Cancer 
Therapy (FACT-G), assessing physical well- being, social/family  well - being, emotional well-being 
and functional well-being, with the Bone Marrow Transplantation Sub- scale (BMTS) to measure 
BMT -specific concerns ( McQuellon 1997) . 
The EQ -5D is a group of instruments that was developed to assess patient -reported health- related 
QoL ( EuroQol Group 1990). The EQ -5D-5L includes the EQ- 5D descriptive system and the EQ 
visual analog scale (EQ VAS). The EQ -5D descriptive system comprises 5 dimensions: mobility, 
self-care, usual activities, pain/discomfort, and anxiety/depression. In the EQ-5D- 5L, each 
dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The patient is asked to indicate his or her health state by [CONTACT_659676] [ADDRESS_889661] 3 responses to each question instead of 5. 
In this study, the EQ- 5D-5L will be used for individuals ≥12 years of age, the EQ -5D- Y for 
children 8 to  11 years of age, and the EQ-5D- Y Proxy Version 1 for children ≤7 years of age. Data 
for children <4 years of age will also be collected using the EQ-5D-Y Proxy Version 1, but these 
results will be analyzed separately from the results for children 4 to 7 years of age. 
The EQ -5D-5L, the EQ-5D-Y, and the EQ-5D-Y Proxy Version 1 include the EQ Visual Analog 
Scale (VAS). The EQ VAS records the patient’s self -rated health on a vertical visual analog scale, 
where the endpoints are labeled “The bes t health you can imagine” and “The worst health you can 
imagine.” Quality  of life measures should be completed as indicated in the SoA and prior to any study 
procedures at the visit. 
8.2.5. Virus -specific T Cell  Assessment  
Patient  peripheral blood mononuclear cells will be assessed for the presence of each of the viral- 
specific virus -reactive T cells using enzyme-linked immunospot. See Section 1.3. 
8.3. Infection Assessments 
Infection assessments will be performed for all patients who, in the opi[INVESTIGATOR_689], 
might meet the criteria described in Appendix 8, Section  10.8. It is very important to ensure that all 
procedures, as outlined in the SoA, are performed for infection assessment immediately prior to the initiation of treatment of viral diseases or initiation of preemptive therapy (ie, on the day anti- viral therapy is initiated).  
A symptom checklist should be completed in the infection assessment eCRF. 
Patients  will continue to be followed in the study and complete all remaining visits through Week 
26 as outlined in the SoA. 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, [ADDRESS_889662] result to make the decision. Whenever it is deemed clinically necessary to use a local laboratory, a plasma sample should also be collected and sent to the central laboratory.  
8.3.2. Samples When  Initiating Anti -viral Therapy  
If antiviral therapy is to be initiated, it is mandatory to send a plasma sample for AdV, BKV, CMV, HHV-6, and JCV and a PBMC sample for EBV for DNA PCR testing to t he central laboratory 
immediately prior to (ie, on the day of) initiating treatment for AdV, BKV, CMV, EBV, HHV-6, or JCV disease or preemptive therapy in ALL instances.  As clinically indicated, stool, urine, and/or 
CSF samples should be collected for AdV,  BKV, CMV, EBV, HHV-6, and JCV and sent to the 
central laboratory as feasible (see Appendix 8, Section 10.8.)  
When local laboratory test results  are used for initiating anti-viral therapy, two plasma (and PBMC 
for EBV) samples for PCR testing must be sent to the central laboratory. The first sample  must be 
collected immediately prior to (ie, on the day of) initiating anti-viral therapy. The second sample 
must be collected [ADDRESS_889663] 
also be reported in such instances. 
8.4. Safety Asse ssments 
Planned time points for all safety assessments are provided in the SoA ( Section 1.3).  
8.4.1. Physical Examinations  
• A complete physical examination will include, at a minimum, assessments of 
the Cardiovascular, Respi[INVESTIGATOR_696], Gastrointestinal and Neurological systems and skin. 
• Investigators should pay special attention to clinical signs related to previous serious illnesses.  
• Physical examinations will be performed and height and weight will be collected as indicated in Section 1.3. The complete physical examination will be overseen by [CONTACT_91432] a Sub-Investigator who is a physician. New abnormal physical examination findings must be documented and will be followed by a physician or other qualified staff at the next scheduled  visit.  
 
8.4.2. Vital  Signs  
• Temperature, pulse rate, O2 saturation, respi[INVESTIGATOR_697], and blood pressure will be assessed.  
• Blood pressure and pulse measurements will be assessed with a completely 
automated device. Manual techniques will be used only if an automated device is not 
available.  
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 62 of 106  
 • Vital signs will be measured in a semi-supi[INVESTIGATOR_55848] [ADDRESS_889664] and will 
include temperature, systolic and diastolic blood pressure, and pulse and respi[INVESTIGATOR_697]. 
8.4.3. Electrocardiograms  
• Single 12-lead electrocardiograms (ECG) will be obtained as outlined in the SoA 
(see S ection 1.3) using an ECG machine that automatically calculates the heart rate 
and 
measures PR, QRS, QT, and QTc (corrected  using Fredericia’s and Bazett’s methods) 
intervals.  
• The ECG will be performed within 1 hour after study treatment administration on 
visits with administration of study  therapy. 
 
8.4.4. Clinical Safety Laboratory Assessments 
• See Appendix 2 ( Section 10.2) for the list of clinical laboratory tests to be performed 
and to the SoA ( Section 1.3) for the timing and frequency. 
• Samples will be sent to the appropriate central laboratory(ies) following the procedure(s) described in the lab manual.  
• The Investigator must review the laboratory report, document this review, and record any clinically significant changes occurring during the study as an AE. The  laboratory reports 
must be filed with the source documents. 
• Abnormal laboratory findings associated with the underlying disease are not considered clinically significant unless judged by [CONTACT_78782]'s  condition. 
• All laboratory tests with values considered clinically significantly abnormal during participation in the study or within [ADDRESS_889665] dose of study intervention should be repeated until the values return to normal or baseline or are no longer considered clinically significant by [CONTACT_47998]. 
o If clinically significant values do not return to normal/baseline within a period of 
time judged reasonable by [CONTACT_737], the etiology should be identified, and the Sponsor notified. 
o All protocol-required laboratory tests, as defined in Appendix 2 ( Section 10.2),  
must be conducted in accordance with the laboratory manual and the SoA ( Section  
1.3). 
o If laboratory values from non-protocol specified laboratory tests performed at 
the institution’s local laboratory require a change in participant management or 
are considered clinically significant by [CONTACT_737] (eg, SAE or AE or dose 
modification), then the results must be recorded.  
• Assessment of blood cell counts and renal function will be monitored for anti-
viral toxicity  
 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 63 of 106  
 8.4.5. Pregnancy  Testing  
• A serum pregnancy test will be performed at screening for all female patients of 
childbearing potential. Prior to treatment assignment, a urine pregnancy test will be performed. If the urine pregnancy test result is negative, the patient will be eligible for treatment assignment and the remainder of the Day 1 testing/procedures will be performed. If the urine pregnancy result is positive, the patient must not be assigned to treatment and should reflex to a β -HCG blood test before screen failing. See S ection 
1.3 
• A urine pregnancy test will be performed prior to each treatment for female patients 
who are of childbearing potential. See S ection  1.3. 
8.4.6. Suicidal Ideation and Behavior Risk Monitoring  
This section is not applicable.  
8.5. Adverse Events (AEs), Serious Adverse Events (SAEs), and Other Safety 
Reporting  
• The definitions of AEs and SAEs can be found in Appendix 3 ( Section  10.3). 
• The definitions of unsolicited and solicited AEs can be found in Appendix 3 
(Section  10.3 ). 
• AEs will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate,  
or the participant's legally authorized representative).  
• The Investigator and any qualified designees are responsible for detecting, 
documenting, and recording events that meet the definition of an AE or SAE and remain 
responsible for following up all AEs OR AEs that are serious, considered related to the study intervention or study procedures, or that caused the participant to discontinue the 
study intervention or study (see S ection  7). 
• The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 4 (Section 10.6).  
8.5.1. Time Period and Frequency for Collecting AE and SAE  Information 
• All AEs and SAEs will be collected at the time points specified in the SoA ( Section 
1.3) from signing of informed consent  until study participation is  complete.  
• Medical occurrences that begin before treatment assignment but after obtaining  informed
 
consent /assent  will be recorded as Medical History/Current Medical Conditions, not as 
AEs.  
• All SAEs will be recorded and reported to the Sponsor or designee immediately and 
under no circumstance should this exceed 24 hours, as indicated in Appendix 3 
(Section  10.3 ). The Investigator will submit any updated SAE data to the Sponsor 
within 24 hours of it being available.  
• Investigators are not obligated to actively seek information on AEs or SAEs after conclusion of the study participation. However, if the Investigator learns of any SAE, 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 64 of 106  
 including a death, at any time after a participant has been discharged from the study, 
and he/she considers the event to be reasonably related to the study intervention or study participation, the Investigator must promptly notify the Sponsor. 
8.5.2. Method of Detecting AEs and  SAEs  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and non-
leading verbal questioning of the participant is the preferred method to inquire about AE occurrences.  
8.5.3. Follow- up of AEs and SAEs  
After the initial AE/SAE report, the Investigator is required to proactively follow each participant at subsequent visits/contacts. All SAEs, and AEs of special interest (as defined in Section 8.5.7), will be followed until resolution, stabilization, the event is otherwise explained, or t he participant is 
lost to follow -up (as defined in Section 7.4). Further information on follow- up procedures is 
provided in Appendix 4 ( Section 10.6).  
8.5.4. Regulatory Reporting Requirements for SAE s 
• Prompt notification by [CONTACT_659677] a study intervention under clinical investigation are met. 
• The Sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation. The Sponsor will comply with country- specific regulatory 
requirements relating to safety reporting to the regulatory authority, Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), and Investigators. 
• An Investigator who receives an Investigator safety report describing an SAE or 
other specific safety informatio n (eg, summary or listing of SAEs) from the Sponsor 
will review and then file it along with the Investigator’s Brochure and will notify the 
IRB/IEC, if appropriate, according to local requirements. 
• Investigator safety reports must be prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R) according to local regulatory requirements and Sponsor policy and forwarded to Investigators as necessary.  
[IP_ADDRESS]. Expedited  Reporting  
The Sponsor/designee will report all relevant information about S[LOCATION_003]Rs that are fatal or life - 
threatening as soon as possible to the FDA, applicable competent authorities in all the Member States concerned, and the Central Ethics Committee, and in any case no later than 7 days after knowledge by [CONTACT_1034]/designee of such a case. Relevant follow- up information will 
subsequently be communicated within an additional [ADDRESS_889666] knowledge by [CONTACT_1034]/designee. 
The Sponsor/designee will also report any additional expedited safety reports required in 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 65 of 106  
 accordance with the timelines outlined in country -specific legislation.  
The Sponsor/designee will also inform all Investigators as required per local regulation. 
The requirements  above refer to the requirements relating to the investigational medicinal product. 
8.5.5. Pregnancy  
• Details of all pregnancies in female participants will be collected after the start of 
study intervention and until [ADDRESS_889667] dose of study intervention. 
• If a pregnancy is reported, the Investigator will record pregnancy information on the appropriate form and submit it to the Sponsor within 24 hours of learning of the [female 
participant or female partner of male participant (after obtaining the necessary signed 
informed consent from the female partner)] pregnancy.  
• While pregnancy itself is not co nsidered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be reported as an AE or  SAE.  
• Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs and will be reported as such.  
• The patient will be followed to determine the outcome of the pregnancy. The Investigator 
will collect follow -up information on the participant and the neonate and the information 
will be forwa rded to the Sponsor. 
• Any post-study pregnancy- related SAE considered reasonably related to the 
study intervention by [CONTACT_659678] 8.5.4. While the Investigator is not obligated to actively 
seek this information in former study participants, he or she may learn of an SAE through spontaneous reporting. 
• Any female participant who becomes pregnant while participating in the study will discontinue study intervention. 
 
8.5.6. Cardiovascular and Death Events  
This section  is not applicable. 
8.5.7. Adverse Events of Special  Interest  
Adverse events of special interest (AESIs) include infusion- related AEs, acute and chronic GVHD, 
and CRS. C riteria for acute and chronic GVHD and CRS can be found in Appendix 5 ( Section 
10.5) and Appendix 6 ( Section  10.6), respectively.  
[IP_ADDRESS]. Special Situation  Reports  
Special  situation reports include reports of overdose, misuse, abuse, medication error, and reports 
of adverse reactio ns associated with product complaints. 
• Overdose: Refers to the administration of a quantity of a medicinal product given per 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 67 of 106  
 8.8. Biomarkers  
• Biomarkers are not evaluated in this  study. 
8.9. Immunogenicity Assessments  
• Immunogenicity assessments are not evaluated in this study. 
8.10. Medical Resource Utilization and Health Economics  
• Hospi[INVESTIGATOR_659656]- admission rates are assessed in this  study. 
 
 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 72 of 106  
 9.4.5. Safety  Analysis 
All safety data will be summarized by [CONTACT_9084], stratum,  
. For Cohort OL, results will be presented by [CONTACT_504176], 
as all patients in Cohort OL receive only ALVR 105.. Categorical endpoints will be summarized 
using the number and percentage of patients  within each category. Continuous endpoints will be 
summarized descriptively with summary statistics (number of non -missing observations, arithmetic 
mean, standard de viation, median, minimum, and maximum).  
Adverse events will be coded using the Medical Dictionary for Regulatory Activities. A treatment 
emergent adverse event (TEAE) is defined as an AE with onset or worsening on or after the first dose of study treatment. TEAEs will be summarized by [CONTACT_659679] (according to the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] v5.0) and by [CONTACT_78487]. The incidence of SAEs will be summarized.  
The incidence of AEs of special interest (AESIs), including acute and chronic GVHD and CRS, and their corresponding exact binomial 95% confidence intervals will be presented. 
Descriptive statistics will be provided for continuo us clinical laboratory, vital sign, and ECG data 
for both the raw data and change from baseline. Abnormal laboratory results will be graded 
according  to NCI CTCAE v5.0, if applicable. Shift tables, presenting the 2- way frequency 
tabulation for baseline and the worst post-baseline value according to the NCI CTCAE grade, will be provided for selected clinical laboratory tests.  
9.4.6. Other Analyses 
The baseline demographics of participants, such as age and gender, etc., will be summarized by [CONTACT_659680]. Continuous variables will be analyzed using a two- sided, two- sample t -test to test for a difference in means between treatment groups.  Categorical 
variables will be analyzed using a two -sided, Fisher’s Exact Test to test for a difference in 
proportions between treatment groups. 
9.5. Interim Analyses  
A review by [CONTACT_659681] [ADDRESS_889668] 
complet ed 30 days of treatment. At this time an assessment of benefit, risk, and process will be 
done, and study optimization will be considered.  
  
A sample size re- estimation (SSRE) and futility analyses will be performed.  
The planned interim analyses will be described in greater detail in a separate document.  
9.5.1. Stoppi[INVESTIGATOR_114907]  
[IP_ADDRESS]. Stoppi[INVESTIGATOR_659657] -party 
allogeneic T cells, the incidence and severity of GVHD and CRS will be monitored during the study. 

AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 73 of 106  
 No patients  will be permitted to receive subsequent infusions of ALVR105  or placebo if: 
1. They develop irreversible, life-threatening, Grade [ADDRESS_889669] ALVR105  dose that is 
considered related to study treatment administration. If this occurs, the patient’s toxicitie s 
will be followed until resolution or until the patient’s participation in the study  ends, 
2. Receive any other hematopoietic stem cell  product, 
3. Receive therapy for relapse of the patient’s primary  malignancy, 
4. Develop Grade 3 or 4 CRS  that persists beyond 72 hours.  
  
[IP_ADDRESS]. Stoppi[INVESTIGATOR_659658] 3 patients experience SAEs that meet the following criteria:  
• CTCAE Grade  3 
• Considered related by [CONTACT_737] 
• Occur during the Treatment Period following the initial dose 
• Cannot be reasonably attributed to the patient’s underlying disease, other 
medical condition, or concomitant medications  
If this occurs, treatment assignment will not resume until there has been a thorough review of all safety data to date and concluded that it is safe for the study to continue. 
 
 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 74 of 106  
 10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations 
10.1.1. Regulatory and Ethical Considerations 
• This study will be conducted in accordance with the protocol and with the following: 
o Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical  Guideli nes 
o Applicable International Council on Harmonisation (ICH) Good Clinical 
Practice (GCP)  Guidelines 
o Applicable laws and  regulations 
• The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
documents (eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_6661]/IEC before the study is initiated.  
• Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study  participants.  
• Protocols and any substantial amendments to the protocol will require health authority approval prior to initiation except for changes necessary to eliminate an immediate hazard to s tudy participants.  
• The Investigator will be responsible for the following: 
o Providing written summaries of the status of the study to the IRB/IEC annually 
or more frequently in accordance with the requirements, policies, and procedures established by [CONTACT_1201]/IEC  
o Notifying the IRB/IEC of SAEs or other significant safety findings as required 
by [CONTACT_1744]/IEC  procedures 
o Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 Code of Federal Regulations (CFR), ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), 
European Medical Device Regulation 2017/745 for clinical device research (if 
applicable), and all other applicable local  regulations 
 
10.1.2. Financial Disclosure 
Investigators and sub-Investigators will provide the Sponsor with sufficient, accurate financial 
information  as requested to allow the Sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study. 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 75 of 106  
 10.1.3. Informed Consent  Process  
• The Investigator or his/her representative will explain the nature of the study to the 
participant or their legally authorized representative and answer all questions  
regarding the study. 
• Participants must be informed that their participation is voluntary. Participants or their legally authorized representative will be r equired to sign a statement of informed 
consent that meets the requirements of [ADDRESS_889670] (HIPAA) requirements, where applicable, and the IRB/IEC or study center.  
• The medical record must include a statement that written informed consent was obtained before the participant was enrolled in the study and the date the written consent was obtained. The authorized person obtaining the informed consent must also sign the ICF. 
• Participants must be re -consented to the most current version of the ICF(s) during 
their participation in the  study. 
• A copy of the ICF(s) must be provided to the participant or their legally authorized representative.  
10.1.4. Data  Protection  
• Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant 
records or datasets that are transferred to the Sponsor will contain the identifier only; 
participant names or any information which would make the participant identifiable will not be transferred. 
• The participant must be informed that his/her personal study- related data will be used 
by [CONTACT_9324]. The level of disclosure must also be explained to the participant who will be required to give consent for their data to be used as described in the informed  consent 
• The participant must be informed that his/her medical records may be examined by [CONTACT_9325], by [CONTACT_6667]/IEC members, and by [CONTACT_6668]. 
 
10.1.5. Committee  Structure  
[IP_ADDRESS]. Clinical Adjudication  Committee  
The CAC will determine the definition of AdV, BKV, CMV, EBV, HHV-6, or JCV end organ disease (see CAC charter).  
[IP_ADDRESS]. Data Safety Monitoring Board 
A review  by [CONTACT_659681] [ADDRESS_889671] completed 30 days of 
treatment and throughout the study as indicated in the DSMB charter (see DSMB charter). 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, [ADDRESS_889672] be available for inspection by [CONTACT_1622], the Sponsor or their 
designee, applicable foreign health authorities, and the IRB/IEC as appropriate. Patients or their 
legal representatives may request their medical information be given to their personal physician or other appropriate medical personnel responsible for their welfare. 
Patient  medical information obtained during the study is confidential and disclosure to third parties 
other than those noted above is prohibited. 
10.1.7. Data Quality Assurance 
• All pa rticipant data relating to the study will be recorded on printed or electronic 
CRF unless transmitted to the Sponsor or designee electronically (eg, laboratory 
data). The Investigator is responsible for verifying that data entries are accurate and correct by [CONTACT_1189].  
• Guidance on completion of CRFs will be provided in the Study Manual.  
• The Investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory agency inspections and provide direct access to source data documents. 
• Quality tolerance limits (QTLs) will be pre -defined to identify systematic issues that can 
impact participant safety and/or reliability of study results. These pre -defined parameters 
will be monitored during the study and important deviations from the QTLs and remedial actions taken will be summarized in the clinical study  report.  
• Monitoring details describing strategy (eg, risk-based initiatives in operations and quality such as Risk Management and Mitigation Strategies and Analytical Risk -Based 
Monitoring), methods, responsibilities and requirements, including handling of noncompliance issues and monitoring techniques (central, remote, or on- site 
monitoring) are provided in the Monitoring Plan.  
• The Sponsor or designee is responsible for the data management of this study including quality checking of the data.  
• The Sponsor assumes accountability for actions delegated to other individuals (eg, Contract Research  Organizations). 
• Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by [CONTACT_13177] 5 years after study completion unless local regulations or institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the Sponsor. No records may be transferred to another location or party without written notification to the Sponsor. 
10.1.8. Source Documents  
• Source documents provide evidence for the existence of the participant and substantiate the integ rity of the data collected. Source documents are filed at the 
Investigator’s site. 
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 77 of 106  
 • Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must 
be explaine d. The Investigator may need to request previous medical records or transfer 
records, depending on the study. Also, current medical records must be available.  
• Definition of what constitutes source data can be found in the Study Manual.  
• The Investigator must maintain accurate documentation (source data) that supports 
the information entered in the CRF.  
• Study monitors will perform ongoing source data verification to confirm that data entered into the CRF by [CONTACT_351943], legible, complete, 
original, attributable, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory  requirements.  
 
10.1.9. Study and Site Start and Closure 
[IP_ADDRESS]. First Act of  Recruitment  
The study start date is the date on which the clinical study will be open for recruitment  of 
participants.  
The first act of recruitment is the activation of the first open site in the Interactive Response System (IRS) and will be the study start date. 
[IP_ADDRESS]. Study/Site  Termination  
The Sponsor or designee reserves the right to close the study site or terminate the study at any time 
for any  reason at the sole discretion of the Sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies have been collected and a study -site closure visit has been performed. 
The Investigator may initiate study- site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination. 
Reasons  for the early closure of a study site by [CONTACT_67837]:  
For study termination: 
• Discontinuation of further study intervention development  
For site  termination:  
• Failur e of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines 
• Inadequate or no recruitment (evaluated after a reasonable amount of time) of 
participants by [CONTACT_737] 
• Total number of participants included earlier than expected  
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 78 of 106  
 If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the 
Investigators, the IECs/IRBs, the regulatory authorities, and any contra ct research organization(s) 
used in the study of the reason for termination or suspension, as specified by [CONTACT_1214]. The Investigator shall promptly inform the participant and should assure appropriate participant therapy and/ or follow -up 
10.1.10. Publication  Policy  
Following completion of the study, the data may be considered for publication in a scientific journal and/or for reporting at a scientific meeting. Each Investigator is obligated to keep data pertaining to the study confidential. The Investigator must consult with the Sponsor before any study data are submitted for publication. The Sponsor reserves the right to deny publication rights until mutual agreement on the content, format, interpretation of data in the manuscript, and journal selected for publication are achieved.  
  
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 79 of 106  
 10.2. Appendix 2: Clinica l Laboratory Tests 
• The tests detailed in Table 5: Protocol-Required Safety Laboratory Tests  will be performed by 
[CONTACT_19690]. 
• Local laboratory results are only required in the event that the central laboratory results 
are not available in time for either study intervention administration and/or response evaluation. If a local sample is required, it is important that the sample f or central 
analysis is obtained at the same time. Additionally, if the local laboratory results are used to make either a study intervention decision or response evaluation, the results must be recorded.  
• Protocol-specific requirements for inclusion or exclusion of participants are detailed 
in Section 5  of the protocol. 
• Additional tests may be performed at any time during the study as determined 
necessary by [CONTACT_9332]. 
 
  
AlloVir 
Clinical Study Protocol P -105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 80 of 106  
 Table 5: Protocol-Required Safety Laboratory Tests 
Clinical Chemistry Panel (Central Laboratory) 
Alanine aminotransferase  Albumin  
Alkaline  phosphatase Amylase  
Aspartate aminotransferase Bicarbonate  
Blood urea nitrogen Calcium  
Chloride Creatine  kinase 
Creatinine  Direct  bilirubin  Gamma -glutamyl transferase  
Glucose Inorganic phosphorus 
Lactate dehydrogenase Lipase  
Potassium Sodium 
Total  bilirubin  Total protein  
Uric acid  
 
Hematology (Central Laboratory) 
Hematocrit  Hemoglobin 
Platelets  Red blood cell count 
White blood cell count and differential [1] 
1. Manual  microscopic review  is performed  only if white  blood cell  count  and/or  differential  values  are out  of reference 
range.  
 
Viral Load in Blood and Urine (Central Laboratory) 
Adenovirus BK virus  
Cytomegalovirus Epstein -Barr virus 
Human  herpesvirus 6 JC virus 
When  viral load determination  is performed  in the laboratory,  residual  viral deoxyribonucleic  acid (DNA)  will be stored  for 
potential viral sequencing and genotypi[INVESTIGATOR_659659].  
Viral load determination at screening may be performed at a local or central laboratory  for the purpose of determining 
eligibility/inclusion. If the results from the local laboratory are used for determination of eligibility/inclusion,  an additional 
pre-randomization sample for viruria testing must be collected for assay at the central laboratory. These results do not have to 
be available at the time of randomization or study treatment infusion. Additional post -infusion samples may be c ollected, as 
clinically indicated.  
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 81 of 106  
 Urinalysis (Local Laboratory) 
Bilirubin  Blood 
Glucose Ketones  
Leukocyte esterase  Nitrite  pH 
Protein  Specific gravity 
Urobilinogen 
Stool Specimen (Central Laboratory)  
Adenovirus Cytomegalovirus 
If a stool specimen is clinically indicated, stool samples will also be sent to the central laboratory for research purposes.  
 
Cerebrospi[INVESTIGATOR_659660] (Central Laboratory) Cytomegalovirus
 Human 
herpesvirus [ADDRESS_889673] [1] Urine pregnancy test  [1] 
Follicle -stimulating  hormone [2] Peripheral blood mononuclear cells (PBMCs)  
and plasma [3] 
Serology (HIV antibody, hepatitis B surface antigen [HBsAg], and hepatitis C virus antibody) 
along with confirmatory tests if  requested  
Virus Specific T -cell Assessment  
1. For female patients of childbearing potential only. A serum ( β-human chorionic gonadotropin) pregnancy test will be 
performed  at screening. A urine  pregnancy  test will be performed  prior  to dosing for female patients  who are  of 
childbearing potential.  
2. Follicle -stimulating  hormone  will be tested  at screening  for women  of nonchildbearing potential  who are 
postmenopausal, defined as 12 consecutive months with no menses without an alternative medical  cause.  
3. At each time-point  indicated  in the SoA s (Section 1.3), blood will be collected  into a cell separation  tube and processed  
to generate a PBMC fraction and a plasma fraction. Genomic DNA will be extracted from the PBMC fraction. The 
genomic DNA from PBMC and plasma fractions will be cryopreserved for potential future evaluation of virus -specific 
T cell persistence (PBMC fraction) and for future evaluation of cytokines and/or other humoral markers of 
inflammation/immune function (plasma fraction). 
 
Investigators must document their review of each laboratory safety report. 
  
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 89 of 106  
 10.4. Appendix 4: Contraceptive and Barrier Guidance 
10.4.1. Definitions  
Woman of Childbearing Potential (WOCBP) 
Women in the following categories are considered WOCBP (fertile):  
1. Following menarche  
2. From the time of menarche until becoming post-menopausal unless permanently 
sterile (see below) 
• A postmenopausal state is defined as no menses for 12 months without an alternative medical  cause.  
o A high follicle -stimulating hormone (FSH) level in the postmenopausal range 
may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therapy (HRT). However, in the absence 
of [ADDRESS_889674] discontinue 
HRT to allow confirmation of postmenopausal status before study enrollment.  
• Permanent sterilization methods (for the purpose of this study) include: 
o Documented  hysterectomy  
o Documented bilateral  salpi[INVESTIGATOR_1656] 
o Documented bilateral  oophorectomy 
o For individuals with permanent infertility due t o an alternate medical cause other 
than the above, (eg, Mullerian agenesis, androgen insensitivity, gonadal 
dysgenesis), Investigator discretion should be applied to determining study entry. 
Note: Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.  
• If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before first dose of study intervention, additional evaluati on should be considered.  
 
Woman of Nonchildbearing Potential (WONCBP) 
Women in the following categories are considered WONCBP:  
3. Premenopausal female with permanent infertility due to one of the following: 
a. Documented  hysterectomy  
b. Documented bilateral  salpi[INVESTIGATOR_1656] 
c. Documented bilateral  oophorectomy 
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 90 of 106  
 d. For individuals with permanent infertility due to an alternate medical cause other 
than the above, (eg, Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), Investigator discretion should be applied to determining study entry. 
Note : Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.  
4. Postmenopausal female  
a. A postmenopausal state is defined as no menses for 12 months without an alternative medical  cause.  
i. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with more than one FSH measurement  
>40 IU/L or mIU/mL is required. 
ii. Females on HRT and whose menopausal status is in doubt must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.  
  
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 91 of 106  
 10.4.2. Contraception  Guidance  
CONTRACEPTIVES ALLOWED DURING THE STUDY INCLUDE:  
Highly Effective Methods That Have Low User Dependency Failure rate of <1% per year when used 
consistently and correctly.  
• Implantable progestogen -only hormone contraception associated with inhibition of  ovulationb 
• Intrauterine device  (IUD)  
• Intrauterine hormone -releasing system (IUS)  b 
• Bilateral tubal occlusion 
• Azoospermic  partner (vasectomized or due to a medical  cause)  
Azoospermia is a highly effective contraceptive method provided that the partner is the sole sexual partner of the 
woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional highly 
effective method of contraception should be used. Spermatogenesis cycle is approximately 90 days.  
Note: documentation of azoospermia for a male participant can come from the site personnel’s review of the 
participant’s medical records, medic al examination, or medical history interview. ) 
Highly Effective Methods That Are User Dependent Failure rate of <1% per year when used consistently and 
correctly.  
Combined (estrogen - and progestogen -containing) hormonal contraception associated with inhibition of 
ovulation  
− oral 
− intravaginal  
− transdermal  
− injectable  
Progestogen -only hormone contraception associated with inhibition of ovulation  
− oral 
− injectable  
Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lif estyle of the 
participant.)  
Effective Methodsd That Are Not Considered Highly Effective Failure rate of ≥1% per year when used  
consistently and correctly.  
• Progestogen- only oral hormonal contraception where inhibition of ovulation is not the primary mode of 
action  
• Male or female condom with or without  spermicide  
• Cervical cap, diaphragm, or sponge with  spermicide  
• A combination  of male  condom  with either  cervical  cap, diaphragm,  or sponge  with spermicide  (double - 
barrier  methods)c 
a. Contraceptive use by [CONTACT_103092].  
b. Failure rate of <1% per year when used consistently and correctly. Typi[INVESTIGATOR_659661].  
c. Male condoms must be used in addition to hormonal contraception. If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable contraceptive methods are limited to those which inhibit ovulation as the primary mode of  action.
 
d. Considered effective, but not highly effective - failure rate of ≥1% per year. Periodic abstinence 
(calendar, symptothermal, post -ovulation methods), withdrawal (coitus interruptus), s permicides 
only, and lactational amenorrhea method (LAM) are not acceptable methods of  contraception.  
e. Male condom and female condom should not be used together (due to risk of failure from  friction).  
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 92 of 106  
 10.5. Appendix 5: Graft Versus Host Disease 
Table 6: MAGIC Criteria for Staging and Grading of Acute Graft Versus Host 
Disease  
 
Stage  Skin  
(Active Erythema 
Only)  Liver 
(Bilirubin)   
Upper GI  Lower GI  
(Stool Output/Day)  
0 No active  
(erythematous) 
GVHD rash  <2 mg/dL  No or intermittent  
nausea, vomiting, or 
anorexia  Adult: <500 mL/day or <3 epi[INVESTIGATOR_1841]/day.  
Child: <10 mL/kg per day or <4 
epi[INVESTIGATOR_1841]/day.  
1 Maculopapular rash  
<25% BSA  2-3 mg/dL  Persistent nausea, 
vomiting, or anorexia  Adult: 500 -999 mL/day or  
34 epi[INVESTIGATOR_1841]/day.  
Child: 10 -19.9 mL/kg per day or 4- 6 
epi[INVESTIGATOR_1841]/day.  
2 Maculopapular rash 
25%50% BSA  3.1-6 mg/dL  - Adult: 1000 -1500 mL/day or 57 
epi[INVESTIGATOR_1841]/day.  
Child: 20 -30 mL/kg per day or 7- 10 
epi[INVESTIGATOR_1841]/day.  
3 Maculopapular rash  
>50% BSA  6.1-15 mg/dL  - Adult: >1500 mL/day or >7 epi[INVESTIGATOR_1841]/day. 
Child: >30 mL/kg per day or >10 
epi[INVESTIGATOR_1841]/day.  
4 Generalized 
erythroderma 
(>50% BSA) plus 
bullous formation and desquamation  
>5% BSA  >15 mg/dL  - Severe abdominal pain with or without 
ileus or grossly bloody stool (regardless 
of stool volume).  
Overall clinical grade (based on most severe target organ involvement):  
Grade 0: No Stage 1 to 4 of any organ.  
Grade I: Stage 1 to 2 skin without liver, upper GI, or lower GI involvement.  
Grade II: Stage 3 rash and/or S tage 1 liver and/or Stage 1 upper GI and/or Stage 1 lower GI.  
Grade III: Stage 2 to 3 liver and/or Stage 2 to 3 lower GI, with Stage 0 to 3 skin and/or Stage 0 to 1 
upper GI. Grade IV: Stage 4 skin, liver, or lower GI involvement, with Stage 0 to 1 upper G I. 
BSA = body surface area; GI = gastrointestinal; GVHD = graft versus host disease; MAGIC = Mount Sinai Acute 
GVHD International Consortium.  
Source: Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft -versus -host  disease 
clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant.  
2016;22(1):4- 10. 
 
Table 7: Response Definitions for Acute Graft Versus Host Disease  
Response Term  Definition  
CR Complete resolution of all signs and symptoms of GVHD in all organs without intervening 
salvage therapi[INVESTIGATOR_014].  
PR Improvement of [ADDRESS_889675] 1 involved organ with progression or newly developed GVHD in 1 or 
more organs.  
Progression  Worsening in 1 or more organs by 1 or more stage without improvement in any involved 
organ.  
NR No improvement or deterioration in any organ within 14 days of therapy initiation.  
CR = complete response; GVHD = graft versus host disease; NR = no response; PR = partial response.  
Source: Center for International Blood & Marrow Transplant Research (CIBMTR). Clinical trial endpoints for patie nts with 
acute GVHD. 2009. https ://www.cibmtr.org/Meetings/Materials/GVHDworkshop/pages/index.aspx.  
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 93 of 106  
  
Table 8: National Institutes of Health Gl obal Severity of Chronic Graft Versus Host 
Disease  
Mild Chronic GVHD  Moderate Chronic GVHD  Severe Chronic GVHD  
 
 
[ADDRESS_889676]  
1 organ (not lung) with a score of [ADDRESS_889677] 1 organ with a score of 3 or 
lung score of 2 or 3  
Key points:  
In skin: higher of the 2 scores to be used for calculating global severity.  
In lung: FEV1 is used instead of clinical score for calculating global severity.  
If the entire abnormality in an organ is noted to be unequivocally explained by a non-GVHD documented cause, that organ is 
not included for calculation of the global severity.  
If the abnormality in an organ is attributed to multifactorial causes (GVHD plus other causes), the scored organ will be used for calculation of the global severity regardless of the contributing causes (no downgrading of organ severity score).  
FEV1 = forced expi[INVESTIGATOR_104763]; GVHD = graft versus host disease.  
Source:  Jagasia MH, Greinix  HT, Arora M, et al. National  Institutes  of Health Consensus  Development  Project  on Criteria 
for Clinical Trials in Chronic Graft -Versus-Host -Disease: I. The 2014 Diagnosis and Staging Working Group Rep ort. Biol 
Blood Marrow Transplant . 2015;21:389-401.e1.  
 
Table 9: National Institutes of Health Response Determinations for Chronic Graft 
Versus Host Disease  
Organ  Complete Response  Partial Response  Progression  
 
Skin NIH Skin Score 0 after 
previous involvement  Decrease in NIH Skin Score 
by 1 or more points  Increase in NIH Skin Score by 
1 or more points, except 0 to 1  
 
Eyes  NIH Eye Score 0 after 
previous involvement  Decrease in NIH Eye Score 
by 1 or more points  Increase in NIH Eye Score by 
1 or more points, except 0 to 1  
 
 
Mouth  NIH Modified Oral Mucosa 
Rating Score 0 after previous 
involvement  Decrease in NIH Modified 
Oral Mucosa Rating Score of 
2 or more points  Increase in NIH Modified 
Oral Mucosa Rating Score of 
2 or more points  
 
 
Esophagus   
NIH Esophagus Score 0 after 
previous involvement   
Decrease in NIH Esophagus 
Score by 1 or more points  Increase in NIH Esophagus 
Score by 1 or more points, 
except 0 to 1  
 
 
Upper GI   
NIH Upper GI Score 0 after 
previous involvement   
Decrease in NIH Upper GI 
Score by 1 or more points  Increase in NIH Upper GI 
Score by 1 or more points,  
except 0 to 1  
 
 
Lower GI   
NIH Lower GI Score 0 after 
previous involvement   
Decrease in NIH Lower GI 
Score by 1 or more points  Increase in NIH Lower GI 
Score by 1 or more  points, 
except from 0 to  1 
 
 
Liver  Normal ALT, alkaline 
phosphatase, and total 
bilirubin after  previous  
elevation of 1 or  more   
 
Decrease by 50%   
 
Increase by 2 ×ULN  
 
 
 
 
 
Lungs   
Normal %FEV1 after previous involvement  
 
If PFTs not available, NIH Lung Symptom Score 0 after  
previous involvement  Increase by 10% predicted 
absolute value of %FEV1 
 
If PFTs not available, decrease in NIH Lung Symptom Score by 1 or more  
points  Decrease by 10% predicted 
absolute value of %FEV1 
 
If PFTs not available, increase in NIH Lung Symptom Score by 1 or more points, except 0  
to 1 
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, [ADDRESS_889678] 1 measure  Decrease in NIH Joint and 
Fascia Score by 1 or more 
points or increase in P -ROM 
score by 1 point for any site  Increase in NIH Joint and 
Fascia Score by 1 or more points or decrease in P -ROM 
score by 1 point for any site  
 
 
Global   
Clinician overall severity 
score 0  Clinician overall severity  
score decreases by 2 or more 
points on a 0 -10 scale  Clinician overall severity  
score increases by 2 or more 
points on a 0 -10 scale  
%FEV1 = percent predicted forced expi[INVESTIGATOR_104763]; ALT = alanine aminotransferase; GI = gastrointestinal; 
NIH = National  Institutes  of Health;  PFT = pulmonary  function  test; P-ROM =  photographic range  of motion; ULN  = upper  
limit of  normal.  
Source: Lee ST, Wolff D, Kitko  C, et al. Measuring therapeutic response in chronic graft -versus -host disease. Biol Blood 
Marrow Transplant . 2015;21(6):984- 999. 
 
  
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 95 of 106  
 10.6. Appendix 6: Cytokine Release Syndrome Scale 
For patients who have a presumptive diagnosis of Cytokine Release Syndrome (CRS) based on the 
clinical judgement of the Investigator, CRS will be graded according to the ASTCT Consensus Grading 
for CRS (shown in Table 10 ) rather than by [CONTACT_3989] . ASTCT characterizes CRS as: “A supraphysiologic 
response following any immune therapy that results in the activation or engagement of endogenous or infused T cells and/or other immune effector cells. Symptoms can be progressive, must include fever at the onset, and may include hypotension, capi[INVESTIGATOR_7946] (hypoxia) and end organ dysfunction.” The 
ASTCT Consensus Grading was developed for chimeric antigen receptor (CAR) -T cell therapi[INVESTIGATOR_659662] -T cells and targeted malignant cells is expected, leading to 
substantial rates of CRS. By [CONTACT_22242], CRS remains only a theoretical concern for virus- specific T cells. 
(For additional details, see Appendix 7, Section 10.7 below.) 
Table 10: ASTCT Consensus Cytokine Release Syndrome Grading Scale 
 
 
 
 
 
 
 
 
 
 
 
Note: Organ toxicities associated with CRS may be graded according to CTCAE v5.0 but they do not influence CRS 
grading.  
Note: Grade 5 CRS is defined as death due to CRS in which another cause is not the principle factor leading to the 
outcome.  
1. Fever is defined as temperature ≥ 38.0°C not attributable to any other cause. In patients who have CRS and then 
receive antipyretic  or anticytokine  therapy  such as tocilizumab  or steroids,  fever  is no longer  required  to grade  
subsequent  CRS severity. In this case, CRS grading is driven by [CONTACT_13199]/or  hypoxia.  
2. CRS grade  is determined  by [CONTACT_13200]:  hypotension or hypoxia not  attributable  to any other  cause.  For 
example, a patient with temperature of 39.5 °C, hypotension requiring 1 vasopressor,  and hypoxia requiring low -flow 
nasal cannula is classified as grade 3  CRS. 
BiPAP = bilevel positive airway pressure; CPAP = continuous positive airway pressure; CRS = cytokine release syndrome; CTCAE = Common Terminology Criteria for Adverse Events.  
Sourc e: Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and 
neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625-638.  
 
   
Grade  
CRS Parameter   
1  
2  
3  
4 
Fever [1] ≥38.0° C ≥38.0° C ≥38.0° C ≥38.0° C 
With  
Hypotension  None  Not requiring 
vasopressors  Requiring 
vasopressors  
with or without 
vasopressin  Requiring  multiple 
vasopressors  
(excluding 
vasopressin)  
And/or [2] 
Hypoxia  None  Requiring lowflow 
nasal cannula 
(oxygen delivered 
at ≤6 L/minute)  
or blowby  [CONTACT_659682] 
(oxygen delivered 
at >6 L/minute), 
facemask, 
nonrebreather  
mask, or Venturi 
mask  Requiring 
positive pressure 
(eg, CPAP, BiPAP,  
intubation, 
mechanical ventilation)  
 
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 97 of 106  
 References:  
1 KYMRIAH® (tisagenlecleucel ) suspension for intravenous infusion, prescribing information. 
https://www.novartis.us/sites/www.novartis.us/files/kymriah.pdf . Accessed on  09 Nov 2020.   
2 Tzannou I, Papadopoulou A, Naik S, et al. Off -the-shelf virus -specific T cells to treat BK virus, human 
herpesvirus 6, cytomegalovirus, Epstein- Barr virus, and adenovirus infections after allogeneic hematopoietic 
stem -cell transplantation.  J Clin Oncol . 2017;35(31):3547 -3557.  
3 Porter DL and Maloney DG. Cytokine release syndrome (CRS). Post TW, ed. UpToDate. Waltham, MA. 
Updated 06 Apr 2020.  https://www.uptodate.com/contents/cytokine -release- syndrome -crs. Accessed on [ADDRESS_889679] consensus grading for cytokine release syndrome and 
neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625 -638. 
 
  
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, [ADDRESS_889680] identified on biopsy  
 
OR 
 
• At least 2 suggestive signs or symptoms: diarrhea, abdominal pain, 
ileus, vomiting, GI hemorrhage AND 
• AdV isolated from the stool by [CONTACT_659683] 
• Other causative agents (e.g., bacterial, viral, amebic) ruled out AND  
endoscopic evidence of lesions (macroscopic or micr oscopic) not 
attributed to GVHD (i.e., biopsy-proven) 
 
Adenovirus 
pancreatitis6 • Consistent clinical and imaging findings such as:  
o Suggestive signs or symptoms (abdominal pain, GI 
symptoms)  
o Amylase or lipase >5xULN  
o Imaging (eg, CT scan) findings suggesting pancreatitis  
AND  
 
• AdV identified by [CONTACT_659684]/washings via antigen/IHC or culture OR  
• AdV detected by [CONTACT_659685]  
• Other causes (e.g., gallstones, hypertriglyceridemia, parasites, paramyxovirus, other viruses) ruled out 
 
Adenovirus 
hemorrhagic cystitis  • Clinical signs and symptoms of cystitis, including dysuria, lower 
abdominal pain, and/or other bladder- associated pain or spasms 
AND  
• Grade ≥2 hematuria (per Bedi scale) AND  
• AdV viruria of >5 log 10 copi[INVESTIGATOR_014]/mL AND 
• No other cause for the HC is apparent  
Adenovirus 
nephritis  • At least one of the following:  
o Suggestive signs or symptoms (impaired renal function, proteinuria, microscopic hematuria, hypertension, dysuria)  
o Enlarged kidney on imaging 
o Renal/bladder obstruction AND  
• AdV identified via renal biopsy via antigen/IHC or culture OR  
• AdV detected by [CONTACT_659686] +/- plasma PCR and  other causes (e.g., 
BK virus, JC virus, bacterial and drug -induced) ruled out  
Adenovirus 
encephalitis/myelitis6 • At least one of the following signs/symptoms of encephalitis:  
o Abnormal CSF 
o Focal CNS deficit  
o Cognitive impairment  
o Visual symptoms  
o Seizure  
o Evidence of compatible lesions by [CONTACT_659687] P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 104 of 106 
 controlled phase II trial. Biol Blood Marrow Transplant . 2017;23(3):512‐521. 
doi:10.1016/j.bbmt.2016.12.[ADDRESS_889681] Dis. 2017;64(1):87‐91. 
doi:10.1093/cid/ciw668  
8. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant 
recipi[INVESTIGATOR_840].  Hematol Oncol Clin North Am . 2011;25(1):151-169. doi:10.1016/j.hoc.2010.11.011 
9. Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus 
infection in patients with haematological malignancies and after stem cell transplantation from 
the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis . 
2019;19(8):e260- e272. doi:10.1016/S1473-3099(19)[ZIP_CODE]-[ADDRESS_889682] TW, 
ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (Accessed on June 15, 2020.) 
11. US Food and Drug Administration. Cytomegalovirus in transplantation: Developi[INVESTIGATOR_659663] - Guida nce for industry. https://www.fda.gov/media/112942/download
 
(Accessed on June 15, 2020.)  
12. Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipi[INVESTIGATOR_840] - Guidelines of the American S ociety of Transplantation Infectious Diseases Community of Practice. Clin 
Transplant . 2019;33(9):e13512. doi:10.1111/ctr.[ZIP_CODE] 
13. Azevedo LS, Pi[INVESTIGATOR_659664], Abdala E, et al. Cytomegalovirus infection in transplant recipi[INVESTIGATOR_840].  Clinics (Sao Paulo) . 2015;70(7):515-523. doi:10.6061/clinics/2015(07)[ADDRESS_889683] international consensus guidelines on the management of cytomegalovirus in solid -organ transplantation. Transplantation. 
2018;102(6):900-931. doi:10.1097/TP.[ADDRESS_889684] ion/disease after hematopoietic stem cell 
transplantation. Int J Hematol . 2010;91(4):588-595. doi:10.1007/s12185-010-0569-x 
16. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in 
hematopoietic stem cell transplant recipi[INVESTIGATOR_840]:  Current status, known challenges, and future 
strategies.  Biol Blood Marrow Transplant . 2003;9(9):543-558. doi:10.1016/s1083-
8791(03)[ZIP_CODE]-8 
17. Griffiths PD. Cytomegalovirus. In: Infections of the Central Nervous System, 4
th Ed, Scheld WM, 
Whitley RJ, Marra CM (Eds), Wolters Kluwer Health, Philadelphia 2014. p. 168. 
18. Zöllner SK, Herbrüggen H, Kolve H, et al. Cytomegalovirus retinitis in children and adolescents 
with acute leukemia following allogeneic hematopoietic stem cell transplantat ion. Transpl Infect 
Dis. 2019;21(5):e13089.  
19. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med. 2005;56:29-44. doi:10.1146/annurev.med.56.082103.104727 
20. Rao N, Schepetiuk S, Choudhry M, et al. JC viraemia in kidney transplant recipi[INVESTIGATOR_840]: to act or not to act? Clin Kidney J . 2012;5(5):471- 473. doi:10.1093/ckj/sfs123  
21. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.  Neurology . 2013; 80(15):1430-1438. 
doi:10.1212/WNL.0b013e31828c2fa1 
22. Koralnik IJ. Progressive multifocal leukoencephalopathy (PML): Epi[INVESTIGATOR_623], clinical 
manifestations, and diagnosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. 
https://www.uptodate.com (Accessed on June 15, 2020.)  
  
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, 07 Apr 2021   
Page 105 of 106 
 11. REFERENCES 
Ahmed IA, Farooqi MS, Vander L, et al. Outcomes of hematopoietic cell 
transplantation in patients with germline SAMD9/SAMD9L Mutations. Biol Blood 
Marrow Transplant . 
2019;25(11):2186–2196. doi:10.1016/j.bbmt.2019.07.[ADDRESS_889685] six months of life: The heart of the matter. Mol Genet Metab . 
2019;126(2):117–120. doi:10.1016/j.ymgme.2018.11.[ADDRESS_889686] Dis . 2015;17(2):242-249. 
D'Souza A, Fretham C. Current uses and outcomes of hematopoietic cell transplantation 
(HCT): Center for International Blood & Marrow Transplant Research (CIBMTR) summary 
slides, 2019. Available at https: //www.cibmtr.org (Accessed on April 29, 2020.) 
EuroQol Group (1990- 12-01). "EuroQol --a new facility for the measurement of health -
related quality of life". Health Policy (Amsterdam, Netherlands) . 16 (3): 199–208. 
doi:10.1016/0168- 8510(90)[ZIP_CODE]-9 
Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after 
haemato poietic stem cell transplantation in the era of pre -emptive therapy: a retrospective 
cohort study. Lancet Haematol. 2016;3(3):e119-e127. 
Hill JA, Mayer BT, Xie H, et al. The cumulative burden of double-stranded DNA virus 
detection after allogeneic HCT is associated with increased mortality. Blood. 2017;129(16):2316-2325. doi:10.1182/blood-2016-10-748426. 
Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release 
syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625-638. 
Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of cytomegalovirus infection and 
disease in transplant patients for use in clinical trials. Clin Infect Dis . 2017;64(1):87–91. 
doi:10.1093/cid/ciw668 
McQuellon, R., Russell, G., Cella, D. et al. Quality of life measurement in bone marrow 
transplantation: development of the Functional Assessment of Cancer Therapy-Bone 
Marrow Transplant (FACT- BMT) scale. Bone Marrow Transplant . 1997; 19:357–368. 
https://doi. org/10.1038/sj.bmt.1700672 
Muftuoglu M, Olson A, Marin D, et al. Allogeneic BK virus- specific T cells for 
progressive multifocal leukoencephalopathy. N Engl J Med . 2018;379(15):1443–1451. 
doi:10.1056/NEJMoa1801540 
Mulanovich VE, Jiang Y, Lima M de, Shpall EJ, Champlin RE, Ciurea SO. Infectious 
AlloVir 
Clinical Study Protocol P- 105-202 
Confidential & Proprietary Version 
3.0, [ADDRESS_889687] blood and T- cell depleted haploidentical stem cell transplantation. 
Am J Blood Res . 2011;1(1):98-105. 
Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad- spectrum T cells as 
treatmen t for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 
2014;6(242):242ra83. doi:10.1126/scitranslmed.300882.  
Sedláček, Petr, Petterson T, Robin M, Sivaprakasam P, Vainorius E, Brundage T, Chandak 
A, Mozaffari E, Nichols G, Voigt S. Incidence of Adenovirus Infection in Hematopoietic Stem Cell Transplantation Recipi[INVESTIGATOR_840]: Findings from the AdVance Study. Biology of Blood and Marrow Transplantation, 2019 Apr; 25(4): 810-818. 
Shah NN, Ahn KW, Litovich C, et al. Outcomes of Medicare- age eligible NHL patients 
receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Adv . 2018;2(8):933–
940. doi:10.1182/bloodadvances.[PHONE_13641] Slade M, Goldsmith S, Romee R, DiPersio JF, Dubberke ER, Westervelt P, Uy GL, 
Lawrence SJ. Epi[INVESTIGATOR_659665]. Transpl Infect Dis . 2017 Feb;19(1). 
Tzannou I, Papadopoulou A, Naik S, et al. Off- the-shelf virus- specific T cells to treat BK 
virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem -cell transplantation. J Clin Oncol. 2017;35(31):3547-
57. 
Tzan nou I, Watanabe A, Naik S, et al. "Mini" bank of only 8 donors supplies CMV-
directed T cells to diverse recipi[INVESTIGATOR_840]. Blood Adv . 2019;3(17):2571–2580. 
doi:10.1182/bloodadvances.[PHONE_13642] Wais V, Bunjes D, Kuchenbauer F, Sorror ML. Comorbidities, age, and ot her patient -
related predictors of allogeneic hematopoietic cell transplantation outcomes. Expert Rev 
Hematol . 
2018;11(10):805–816. doi:10.1080/17474086.2018.1509703 
Wittes J, Wallenstein S. The power of the Mantel —Haenszel Test. J Am Stat 
Assoc . 1987;82:400, 1104-1109, DOI: 10.1080/01621459.1987.[ADDRESS_889688] recipi[INVESTIGATOR_840]: the 
multinational AdVance study. Bone Marrow Transpl. 2019 Feb 25. [Epub ahead of print] 